PEG-SO.sub.2 --CH.sub.2 --CH.sub.2 --Cl+W--S--H→PEG--SO.sub.2 --CH.sub.2 --CH.sub.2 --S--W,
PEG--SO.sub.2 --CH═CH.sub.2 +W--S--H→PEG--SO.sub.2 --CH.sub.2 --CH.sub.2 --S--W.
PEG-NH.sub.2 +NHS--O.sub.2 C--CH.sub.2 --CH.sub.2 --SO.sub.2 CH═CH.sub.2 →PEG-NH--OC--CH.sub.2 --CH.sub.2 --SO.sub.2 --CH═CH.sub.2.
PEG-CO.sub.2 --NHS+NH.sub.2 --CH.sub.2 --CH.sub.2 --SO.sub.2 --CH═CH.sub.2 →PEG-CO--NH--CH.sub.2 --CH.sub.2 --SO.sub.2 --CH═CH.sub.2.
R--CH.sub.2 CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --Y
CH.sub.3 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH═CH.sub.2
CH.sub.2 ═CH--SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2)hd n--SO.sub.2 --CH═CH.sub.2
R--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --Y
R--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-W
W--S--CH.sub.2 --SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-W
R--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-protein
protein-S--CH.sub.2 --SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 S-protein
protein-S--CH.sub.2 --CH.sub.2 --SO.sub.2 --CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-protein,
H.sub.3 CO--CH.sub.2 --CH.sub.2 --(OCH.sub.2 CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 --CH.sub.2 --S-protein
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/151,481US5446090A (en) | 1993-11-12 | 1993-11-12 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| DK95901226TDK0728155T3 (en) | 1993-11-12 | 1994-11-14 | Water-soluble active sulfones of poly (ethylene glycol) |
| EE9600128AEE03448B1 (en) | 1993-11-12 | 1994-11-14 | Water-soluble active poly (ethylene glycol) sulfones and methods for their preparation |
| BR9408048ABR9408048A (en) | 1993-11-12 | 1994-11-14 | Water-soluble and hydrolytically stable isolates of active poly (ethylene glycol) and related polymers for the modification of surfaces and molecules |
| UA96062250AUA58481C2 (en) | 1993-11-12 | 1994-11-14 | A water soluble hydrolitically stable activated polymer, a method for preparing the activated polyethylene glycol (variants), a biologically active conjugate |
| JP07514031AJP3114998B2 (en) | 1993-11-12 | 1994-11-14 | Active sulfones of isolable, water-soluble and hydrolytically stable poly (ethylene glycol) and related polymers for surface and molecular modification |
| ES95901226TES2173943T3 (en) | 1993-11-12 | 1994-11-14 | WATER SOLUBLE POLYETHYLENGLYCOL ACTIVE SULPHONES |
| CA002176203ACA2176203C (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
| PL94314298APL180149B1 (en) | 1993-11-12 | 1994-11-14 | method for producing activated poly(ethylene glycol), biologically active conjugate, method for producing poly(ethylene glycol) conjugate, method for producing vinyl sulfone and method for producing haloethyl sulfone |
| KR1019960702507AKR100225746B1 (en) | 1993-11-12 | 1994-11-14 | Poly (ethylene glycol) with water soluble active sulfone |
| HU9601253AHU225649B1 (en) | 1993-11-12 | 1994-11-14 | Isolable, water soluble, hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers to modify surfaces and molecules, process for producing thereof, biologically active conjugates thereof and process for producing said conjugates |
| RU96113123/04ARU2176253C2 (en) | 1993-11-12 | 1994-11-14 | Water-soluble hydrolytically stable activated polymer, method of synthesis of activated polyethylene glycol (variants), biologically active conjugate |
| SK608-96ASK284527B6 (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) and process of their preparation |
| DE69430317TDE69430317T2 (en) | 1993-11-12 | 1994-11-14 | WATER-SOLUBLE ACTIVE SULFONES FROM POLYETHYLENE GLYCOLES |
| CZ19961375ACZ295640B6 (en) | 1993-11-12 | 1994-11-14 | Water soluble, activated and hydrolytically stable polymer, use thereof, hydrolytically stable, biologically active conjugate and use thereof, biological material, method for synthesizing the water soluble, activated polymer and process for preparing the biologically active conjugate |
| RO96-00959ARO118434B1 (en) | 1993-11-12 | 1994-11-14 | Poly(ethylene glycolsulphone) derivatives and process for preparing said derivatives and biological conjugates containing the same |
| AT95901226TATE215577T1 (en) | 1993-11-12 | 1994-11-14 | WATER SOLUBLE ACTIVE SULFONES OF POLYETHYLENE GLYCOLES |
| CN94194460ACN1085689C (en) | 1993-11-12 | 1994-11-14 | Separable, water-soluble and hydrolytically stable reactive polyethylene glycol sulfone and related polymers for surface and molecular modification |
| ROA200000307ARO121855B1 (en) | 1993-11-12 | 1994-11-14 | DERIVATIVES OF POLYETHYLENGLICYL SULFON AND PROCESSES FOR THEIR OBTAINING |
| AU10548/95AAU687937B2 (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
| EP01122161AEP1176160A3 (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
| EP95901226AEP0728155B1 (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
| NZ276313ANZ276313A (en) | 1993-11-12 | 1994-11-14 | Sulphone-substituted polyethers and their use as conjugate carriers with bioactive materials |
| PCT/US1994/013013WO1995013312A1 (en) | 1993-11-12 | 1994-11-14 | Water soluble active sulfones of poly(ethylene glycol) |
| US08/473,734US5739208A (en) | 1993-11-12 | 1995-06-07 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| BG100568ABG63399B1 (en) | 1993-11-12 | 1996-05-06 | ACTIVE SOLFONIC POLYMER DERIVATIVES, IN PARTICULAR TO POLYETHYLENE GLYCOL, METHODS FOR THEIR PREPARATION AND APPLICATION |
| FI962004AFI117441B (en) | 1993-11-12 | 1996-05-10 | Water-soluble active polyethylene glycol sulfones |
| NO19961918ANO315377B1 (en) | 1993-11-12 | 1996-05-10 | Pharmaceutical composition and process for synthesizing poly (ethylene glycol) vinyl sulfone |
| US09/027,679US5900461A (en) | 1993-11-12 | 1998-02-23 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US09/294,188US6610281B2 (en) | 1993-11-12 | 1999-04-19 | Water soluble activated polymers containing an active ethyl sulfone moiety for modification of surfaces and molecules |
| HK02104035.7AHK1042312A1 (en) | 1993-11-12 | 2002-05-30 | Water soluble active sulfones of poly(ethylene glycol) |
| US10/647,621US6894025B2 (en) | 1993-11-12 | 2003-08-25 | Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety |
| US11/112,118US7214366B2 (en) | 1993-11-12 | 2005-04-22 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/151,481US5446090A (en) | 1993-11-12 | 1993-11-12 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/473,734DivisionUS5739208A (en) | 1993-11-12 | 1995-06-07 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| Publication Number | Publication Date |
|---|---|
| US5446090Atrue US5446090A (en) | 1995-08-29 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/151,481Expired - LifetimeUS5446090A (en) | 1993-11-12 | 1993-11-12 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US08/473,734Expired - LifetimeUS5739208A (en) | 1993-11-12 | 1995-06-07 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US09/027,679Expired - LifetimeUS5900461A (en) | 1993-11-12 | 1998-02-23 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US09/294,188Expired - Fee RelatedUS6610281B2 (en) | 1993-11-12 | 1999-04-19 | Water soluble activated polymers containing an active ethyl sulfone moiety for modification of surfaces and molecules |
| US10/647,621Expired - Fee RelatedUS6894025B2 (en) | 1993-11-12 | 2003-08-25 | Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety |
| US11/112,118Expired - Fee RelatedUS7214366B2 (en) | 1993-11-12 | 2005-04-22 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/473,734Expired - LifetimeUS5739208A (en) | 1993-11-12 | 1995-06-07 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US09/027,679Expired - LifetimeUS5900461A (en) | 1993-11-12 | 1998-02-23 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US09/294,188Expired - Fee RelatedUS6610281B2 (en) | 1993-11-12 | 1999-04-19 | Water soluble activated polymers containing an active ethyl sulfone moiety for modification of surfaces and molecules |
| US10/647,621Expired - Fee RelatedUS6894025B2 (en) | 1993-11-12 | 2003-08-25 | Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety |
| US11/112,118Expired - Fee RelatedUS7214366B2 (en) | 1993-11-12 | 2005-04-22 | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| Country | Link |
|---|---|
| US (6) | US5446090A (en) |
| EP (2) | EP1176160A3 (en) |
| JP (1) | JP3114998B2 (en) |
| KR (1) | KR100225746B1 (en) |
| CN (1) | CN1085689C (en) |
| AT (1) | ATE215577T1 (en) |
| AU (1) | AU687937B2 (en) |
| BG (1) | BG63399B1 (en) |
| BR (1) | BR9408048A (en) |
| CA (1) | CA2176203C (en) |
| CZ (1) | CZ295640B6 (en) |
| DE (1) | DE69430317T2 (en) |
| DK (1) | DK0728155T3 (en) |
| EE (1) | EE03448B1 (en) |
| ES (1) | ES2173943T3 (en) |
| FI (1) | FI117441B (en) |
| HK (1) | HK1042312A1 (en) |
| HU (1) | HU225649B1 (en) |
| NO (1) | NO315377B1 (en) |
| NZ (1) | NZ276313A (en) |
| PL (1) | PL180149B1 (en) |
| RO (2) | RO121855B1 (en) |
| RU (1) | RU2176253C2 (en) |
| SK (1) | SK284527B6 (en) |
| UA (1) | UA58481C2 (en) |
| WO (1) | WO1995013312A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0758906A1 (en)* | 1994-06-14 | 1997-02-26 | Tadahiko Kohno | Pegylation reagents and compounds formed therewith |
| US5672662A (en)* | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| WO1998051336A1 (en)* | 1997-05-15 | 1998-11-19 | Theratech, Inc. | Targeted delivery to t lymphocytes |
| US6066673A (en)* | 1998-03-12 | 2000-05-23 | The Procter & Gamble Company | Enzyme inhibitors |
| US6072040A (en)* | 1996-10-15 | 2000-06-06 | Medical Analysis Systems, Inc. | Stabilized conjugates of uncomplexed subunits of multimeric proteins |
| US6129928A (en)* | 1997-09-05 | 2000-10-10 | Icet, Inc. | Biomimetic calcium phosphate implant coatings and methods for making the same |
| US6143866A (en)* | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
| WO2000078285A1 (en)* | 1999-06-18 | 2000-12-28 | University Of Medicine And Dentistry Of New Jersey | Controlled release of therapeutics by in-situ entrapment by matrix cross-linking |
| US6284246B1 (en) | 1997-07-30 | 2001-09-04 | The Procter & Gamble Co. | Modified polypeptides with high activity and reduced allergenicity |
| US6303119B1 (en) | 1999-09-22 | 2001-10-16 | The Procter & Gamble Company | Personal care compositions containing subtilisin enzymes bound to water insoluble substrates |
| US6306820B1 (en) | 1996-12-06 | 2001-10-23 | Amgen Inc. | Combination therapy using a TNF binding protein for treating TNF-mediated diseases |
| US6410017B1 (en) | 1998-09-22 | 2002-06-25 | The Procter & Gamble Company | Personal care compositions containing active proteins tethered to a water insoluble substrate |
| US20020114775A1 (en)* | 1996-09-23 | 2002-08-22 | Incept Llc | Crosslinking agents and methods of use |
| US6495136B1 (en) | 1998-03-26 | 2002-12-17 | The Procter & Gamble Company | Proteases having modified amino acid sequences conjugated to addition moieties |
| US20030044468A1 (en)* | 2001-03-20 | 2003-03-06 | Francesco Cellesi | Two-phase processing of thermosensitive polymers for use as biomaterials |
| WO2003018665A1 (en)* | 2001-08-22 | 2003-03-06 | Bioartificial Gel Technologies Inc. | Process for the preparation of activated polyethylene glycols |
| US6538104B2 (en) | 2001-04-27 | 2003-03-25 | Medical Analysis Systems, Inc. | Stabilization of cardiac troponin I subunits and complexes |
| US20030059906A1 (en)* | 2000-10-19 | 2003-03-27 | Hubbell Jeffrey A. | Block copolymers for multifunctional self-assembled systems |
| US6566115B1 (en) | 1999-07-22 | 2003-05-20 | The Procter & Gamble Company | Protease conjugates having sterically protected clip sites |
| US6569663B1 (en) | 1998-03-26 | 2003-05-27 | The Procter & Gamble Company | Serine protease variants having amino acid substitutions |
| US6586224B1 (en) | 1999-07-22 | 2003-07-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions |
| US6586223B1 (en) | 1999-07-22 | 2003-07-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid substitutions in defined epitope regions |
| US20030157163A1 (en)* | 1998-09-08 | 2003-08-21 | Liang-Chang Dong | Dosage form comprising therapeutic formulation |
| US20030162841A1 (en)* | 1998-12-04 | 2003-08-28 | Incept | Biocompatible crosslinked polymers |
| US20030179692A1 (en)* | 2002-03-19 | 2003-09-25 | Yoshitaka Ohotomo | Storage medium |
| US20030180252A1 (en)* | 1997-11-10 | 2003-09-25 | Lawrence Tamarkin | Methods and compositions for enhancing immune response and for the production of in vitro Mabs |
| US20030191291A1 (en)* | 2000-09-08 | 2003-10-09 | Kochendoerfer Gerd G. | Synthetic erythropoiesis stimulating proteins |
| US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| US20030220245A1 (en)* | 2000-06-02 | 2003-11-27 | Hubbell Jeffrey A | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds |
| US6693083B2 (en) | 1997-08-05 | 2004-02-17 | Watson Pharmaceuticals, Inc. | Conjugates targeted to the interleukin-2 receptor |
| US6706289B2 (en) | 2000-10-31 | 2004-03-16 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| US20040077835A1 (en)* | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
| US20040087778A1 (en)* | 1998-10-23 | 2004-05-06 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20040126361A1 (en)* | 2002-12-26 | 2004-07-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
| US20040136956A1 (en)* | 2002-09-05 | 2004-07-15 | Barker Nicholas P. | Asialo-interferons and the treatment of liver cancer |
| US20040136952A1 (en)* | 2002-12-26 | 2004-07-15 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US20040136955A1 (en)* | 2002-09-05 | 2004-07-15 | Barker Nicholas P | Modified asialo-interferons and uses thereof |
| WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| WO2004063250A1 (en)* | 2003-01-06 | 2004-07-29 | Nektar Therapeutics Al, Corporation | Thiol-selective water-soluble polmer derivatives |
| US6818435B2 (en) | 2000-05-15 | 2004-11-16 | Tecan Trading Ag | Microfluidics devices and methods for performing cell based assays |
| US20040249576A1 (en)* | 2003-03-31 | 2004-12-09 | Xencor | Methods for rational pegylation of proteins |
| US20040268425A1 (en)* | 2003-03-05 | 2004-12-30 | Deliatroph Pharmaceuticals, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20050036978A1 (en)* | 2002-09-09 | 2005-02-17 | Antoni Kozlowski | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US20050048626A1 (en)* | 2003-01-06 | 2005-03-03 | Xencor, Inc. | BAFF variants and methods thereof |
| US20050089970A1 (en)* | 2000-07-12 | 2005-04-28 | Bradburne James A. | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| US20050089515A1 (en)* | 2003-08-29 | 2005-04-28 | Dyax Corp. | Poly-pegylated protease inhibitors |
| US20050114037A1 (en)* | 2003-03-31 | 2005-05-26 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US20050130892A1 (en)* | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
| US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
| US20050175584A1 (en)* | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
| US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
| US20050221443A1 (en)* | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
| US20050228187A1 (en)* | 2004-03-05 | 2005-10-13 | Marie-Pierre Faure | Process for the preparation of activated polyethylene glycols |
| US20050250678A1 (en)* | 2004-01-08 | 2005-11-10 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
| US20050250696A1 (en)* | 1996-07-09 | 2005-11-10 | Fisher Eric F | Truncated soluble tumor necrosis factor type-I and type-II receptors |
| US20050260186A1 (en)* | 2003-03-05 | 2005-11-24 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20050261232A1 (en)* | 2004-04-13 | 2005-11-24 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US20060014248A1 (en)* | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20060019347A1 (en)* | 2004-07-21 | 2006-01-26 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| WO2006009901A2 (en) | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| US20060104968A1 (en)* | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20060127352A1 (en)* | 1999-02-01 | 2006-06-15 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| US20060135586A1 (en)* | 2004-12-21 | 2006-06-22 | Antoni Kozlowski | Stabilized polymeric thiol reagents |
| US20060135427A1 (en)* | 2004-12-22 | 2006-06-22 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| US20070071764A1 (en)* | 2005-04-22 | 2007-03-29 | Sullivan John K | Toxin peptide therapeutic agents |
| US20070137573A1 (en)* | 2005-12-21 | 2007-06-21 | Arnold Kholodenko | Apparatus for an optimized plasma chamber grounded electrode assembly |
| US20070160572A1 (en)* | 1998-11-10 | 2007-07-12 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| WO2007084460A2 (en) | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| WO2007149594A2 (en) | 2006-06-23 | 2007-12-27 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| US20080097083A1 (en)* | 2004-02-02 | 2008-04-24 | Ambrx, Inc. | Modified Human Four Helical Bundle Polypeptides and Their Uses |
| US20080095755A1 (en)* | 2006-07-17 | 2008-04-24 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| US20080108792A1 (en)* | 2005-06-03 | 2008-05-08 | Ambrx, Inc. | Human Interferon Molecules and Their Uses |
| WO2008060780A2 (en) | 2006-10-04 | 2008-05-22 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| US20080153745A1 (en)* | 2005-08-18 | 2008-06-26 | Ambrx, In. | Compositions of tRNA and uses thereof |
| WO2008095063A1 (en) | 2007-01-31 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| US20080255026A1 (en)* | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| US20080255045A1 (en)* | 2007-03-30 | 2008-10-16 | Ambrx, Inc. | Modified FGF-21 Polypeptides and Their Uses |
| US20080253987A1 (en)* | 2007-04-13 | 2008-10-16 | Kuros Biosurgery Ag | Polymeric tissue sealant |
| US20080260802A1 (en)* | 1996-09-23 | 2008-10-23 | Sawhney Amarpreet S | Biocompatible hydrogels made with small molecule precursors |
| US20080317670A1 (en)* | 2005-12-14 | 2008-12-25 | Ambrx, Inc. | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides |
| US20090000924A1 (en)* | 2007-06-29 | 2009-01-01 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
| US20090017097A1 (en)* | 2007-07-09 | 2009-01-15 | Sawhney Amarpreet S | Hydrogel polymeric compositions and methods |
| US20090030451A1 (en)* | 2005-02-09 | 2009-01-29 | Hadba Ahmad R | Synthetic Sealants |
| US20090047349A1 (en)* | 2007-08-13 | 2009-02-19 | Confluent Surgical, Inc. | Drug delivery device |
| US20090075887A1 (en)* | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| EP2042196A2 (en) | 2001-10-10 | 2009-04-01 | Neose Technologies, Inc. | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| US20090098101A1 (en)* | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
| US20090104114A1 (en)* | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US20090118181A1 (en)* | 2007-05-22 | 2009-05-07 | Walker Kenneth W | Compositions and methods for producing bioactive fusion proteins |
| US20090123367A1 (en)* | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US20090137736A1 (en)* | 2005-11-08 | 2009-05-28 | Ambrx, Inc. | Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides |
| WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| US20090148908A1 (en)* | 2007-11-08 | 2009-06-11 | Paciotti Giulio F | Compositions and methods for generating antibodies |
| US20090208454A1 (en)* | 2007-05-02 | 2009-08-20 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| US20090227981A1 (en)* | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
| US20090227689A1 (en)* | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
| US20090281028A1 (en)* | 2006-10-25 | 2009-11-12 | Sullivan John K | OSK1 peptide analogs and pharmaceutical compositions |
| US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| US20100010194A1 (en)* | 2006-11-30 | 2010-01-14 | Nektar Therapeutics Al, Corporation | Method for Preparing a Polymer Conjugate |
| WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| US20100034769A1 (en)* | 2002-03-22 | 2010-02-11 | Kuros Biosurgery, AG | Compositions for tissue augmentation |
| US20100093608A1 (en)* | 2008-09-26 | 2010-04-15 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
| US20100159586A1 (en)* | 2006-09-08 | 2010-06-24 | Ambrx, Inc. | Hybrid Suppressor tRNA for Vertebrate Cells |
| US20100159585A1 (en)* | 2006-09-08 | 2010-06-24 | Ambrx, Inc. | Suppressor tRNA Transcription in Vertebrate Cells |
| US7744912B1 (en) | 1999-02-01 | 2010-06-29 | Eidgenossische Technische Hochschule Zurich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
| WO2010077297A1 (en) | 2008-12-09 | 2010-07-08 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
| US20100183625A1 (en)* | 2009-01-06 | 2010-07-22 | Dyax Corp. | Treatment of Mucositis with Kallikrein Inhibitors |
| US20100222407A1 (en)* | 2005-05-31 | 2010-09-02 | Tatiana Segura | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
| US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| WO2010144629A1 (en) | 2009-06-09 | 2010-12-16 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| US20100330060A1 (en)* | 2003-12-03 | 2010-12-30 | Novo Nordisk A/S | Glycopegylated factor ix |
| US20110014118A1 (en)* | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
| EP2279756A2 (en) | 2005-04-05 | 2011-02-02 | Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. | Method for shielding functional sites or epitopes on proteins |
| WO2011015634A2 (en) | 2009-08-05 | 2011-02-10 | Pieris Ag | Controlled release formulations of lipocalin muteins |
| EP2284191A2 (en) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Process for the preparation of hGH |
| WO2011034604A2 (en) | 2009-09-17 | 2011-03-24 | Baxter Healthcare, S.A. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| US20110086801A1 (en)* | 2002-06-07 | 2011-04-14 | Dyax Corp. | Prevention and reduction of blood loss |
| US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
| US7951614B2 (en) | 2003-12-02 | 2011-05-31 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| EP2327723A2 (en) | 2003-10-10 | 2011-06-01 | Xencor, Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US20110136723A1 (en)* | 2008-07-21 | 2011-06-09 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US20110144307A1 (en)* | 2005-11-16 | 2011-06-16 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
| US20110195483A1 (en)* | 2008-09-26 | 2011-08-11 | Ambrx, Inc. | Non-Natural Amino Acid Replication-Dependent Microorganisms and Vaccines |
| US20110200611A1 (en)* | 2010-01-06 | 2011-08-18 | Dyax Corp. | Plasma kallikrein binding proteins |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US8029782B2 (en) | 2008-10-01 | 2011-10-04 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| US20110269942A1 (en)* | 2007-08-09 | 2011-11-03 | Daiichi Sankyo Company, Limited | Antibodies modified with hydrophobic molecule |
| US8053410B2 (en) | 2002-06-21 | 2011-11-08 | Novo Nordisk Health Care A/G | Pegylated factor VII glycoforms |
| EP2386571A2 (en) | 2005-04-08 | 2011-11-16 | BioGeneriX AG | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US8076292B2 (en) | 2001-10-10 | 2011-12-13 | Novo Nordisk A/S | Factor VIII: remodeling and glycoconjugation of factor VIII |
| WO2012012300A2 (en) | 2010-07-20 | 2012-01-26 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US8137989B2 (en) | 1994-03-18 | 2012-03-20 | Cytimmune Sciences, Inc. | Method for delivering a cytokine using a colloidal metal |
| WO2012065181A2 (en) | 2010-11-12 | 2012-05-18 | Dana Farber Cancer Institute, Inc. | Cancer therapies and diagnostics |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
| WO2012125973A2 (en) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
| EP2514757A2 (en) | 2005-01-10 | 2012-10-24 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
| US8318154B2 (en) | 2008-04-28 | 2012-11-27 | Halozyme, Inc. | Super fast-acting insulin compositions |
| WO2012174478A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| WO2012174480A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
| WO2013006706A1 (en) | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
| EP2548967A2 (en) | 2006-09-21 | 2013-01-23 | The Regents of The University of California | Aldehyde tags, uses thereof in site-specific protein modification |
| WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
| EP2586456A1 (en) | 2004-10-29 | 2013-05-01 | BioGeneriX AG | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
| WO2013063155A2 (en) | 2011-10-24 | 2013-05-02 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| EP2599502A2 (en) | 2003-04-11 | 2013-06-05 | PR Pharmaceuticals Inc. | Method for preparation of site-specific protein conjugates |
| WO2013102211A2 (en) | 2011-12-29 | 2013-07-04 | Walensky Loren D | Stabilized antiviral fusion helices |
| WO2013151774A1 (en) | 2012-04-04 | 2013-10-10 | Halozyme, Inc. | Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane |
| EP2662090A1 (en) | 2008-04-14 | 2013-11-13 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| WO2013185115A1 (en) | 2012-06-08 | 2013-12-12 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| US8663629B2 (en) | 1994-01-11 | 2014-03-04 | Dyax Corp. | Kallikrein-binding “kunitz domain” proteins and analogues thereof |
| WO2014036492A1 (en) | 2012-08-31 | 2014-03-06 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| US8685417B2 (en) | 2006-12-20 | 2014-04-01 | Arkema, Inc. | Polymer encapsulation and/or binding |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US8716239B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF |
| US8716240B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US8716225B2 (en) | 2004-09-27 | 2014-05-06 | Dyax Corp. | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| WO2014099984A1 (en) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US8791066B2 (en) | 2004-07-13 | 2014-07-29 | Novo Nordisk A/S | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] |
| WO2014144148A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
| WO2014144768A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
| US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
| WO2014151369A2 (en) | 2013-03-15 | 2014-09-25 | Dana-Farber Cancer Institute, Inc. | Stabilized ezh2 peptides |
| WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
| EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
| EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
| US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
| US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| WO2015003167A1 (en) | 2013-07-03 | 2015-01-08 | Halozyme, Inc. | Thermally stable ph20 hyaluronidase variants and uses thereof |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| US8980608B2 (en) | 2012-03-30 | 2015-03-17 | The Board Of Regents Of The University Of Oklahoma | High molecular weight heparosan polymers and methods of production and use thereof |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
| US9114144B2 (en) | 2002-06-07 | 2015-08-25 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
| US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
| WO2015175774A1 (en) | 2014-05-14 | 2015-11-19 | Trustees Of Dartmouth College | Deimmunized lysostaphin and methods of use |
| US9205150B2 (en) | 2011-12-05 | 2015-12-08 | Incept, Llc | Medical organogel processes and compositions |
| WO2015191781A2 (en) | 2014-06-10 | 2015-12-17 | Amgen Inc. | Apelin polypeptides |
| US9266964B2 (en) | 2011-01-06 | 2016-02-23 | Dyax Corp. | Method of treating hereditary angioedema using plasma kallikrein binding antibodies |
| US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
| WO2016033555A1 (en) | 2014-08-28 | 2016-03-03 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9310627B2 (en) | 2013-11-15 | 2016-04-12 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| WO2016061286A2 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US9447401B2 (en) | 2011-12-30 | 2016-09-20 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US9579390B2 (en) | 2012-11-12 | 2017-02-28 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| US9605078B2 (en) | 2012-11-16 | 2017-03-28 | The Regents Of The University Of California | Pictet-Spengler ligation for protein chemical modification |
| US9775889B2 (en) | 2008-03-06 | 2017-10-03 | Halozyme, Inc. | Methods of treatment of cellulite |
| US20170360994A1 (en)* | 2014-12-09 | 2017-12-21 | Tangible Science, Llc | Medical device coating with a biocompatible layer |
| WO2018039545A2 (en) | 2016-08-26 | 2018-03-01 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| WO2018170299A1 (en) | 2017-03-15 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of prokaryotic gene transcription and uses thereof |
| WO2018237201A1 (en) | 2017-06-22 | 2018-12-27 | Catalyst Biosciences, Inc. | MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE |
| WO2019018499A2 (en) | 2017-07-19 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
| US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
| US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| WO2019118719A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
| WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| WO2019133399A1 (en) | 2017-12-26 | 2019-07-04 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
| WO2019157131A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| WO2019178313A1 (en) | 2018-03-14 | 2019-09-19 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for biomarker detection |
| US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
| WO2019191482A1 (en) | 2018-03-30 | 2019-10-03 | Becton, Dickinson And Company | Water-soluble polymeric dyes having pendant chromophores |
| US10464975B2 (en) | 2015-07-02 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| WO2020023300A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Treatment of lymmphatic metastases |
| WO2020056066A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| WO2020131871A1 (en)* | 2018-12-19 | 2020-06-25 | Tangible Science, Inc. | Systems and methods of treating a hydrogel-coated medical device |
| WO2020140101A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
| WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| WO2020215005A1 (en) | 2019-04-18 | 2020-10-22 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
| WO2021126827A1 (en) | 2019-12-16 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized oncolytic peptides and uses thereof |
| WO2021127493A1 (en) | 2019-12-20 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof |
| US11046785B2 (en) | 2014-03-27 | 2021-06-29 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| US11078246B2 (en) | 2015-08-28 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Peptides binding to Bfl-1 |
| WO2021178714A2 (en) | 2020-03-04 | 2021-09-10 | Dana-Farber Cancer Institute, Inc. | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF |
| WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| US11142554B2 (en) | 2015-03-18 | 2021-10-12 | Massachusetts Institute Of Technology | Selective Mcl-1 binding peptides |
| WO2021216845A1 (en) | 2020-04-22 | 2021-10-28 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
| WO2021222243A2 (en) | 2020-04-27 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
| WO2021236526A1 (en) | 2020-05-18 | 2021-11-25 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
| US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
| WO2021255524A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
| US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| WO2022081827A1 (en) | 2020-10-14 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
| WO2022098848A1 (en) | 2020-11-05 | 2022-05-12 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
| WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
| WO2023039474A1 (en) | 2021-09-08 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
| US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
| WO2023215784A1 (en) | 2022-05-04 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof |
| WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
| WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
| US11945846B2 (en) | 2016-02-29 | 2024-04-02 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| WO2024196805A1 (en) | 2023-03-17 | 2024-09-26 | Beckman Coulter, Inc. | Benzothienopyrrole cyanine dyes |
| US12102689B2 (en) | 2015-11-09 | 2024-10-01 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| WO2025064842A1 (en) | 2023-09-21 | 2025-03-27 | Beckman Coulter, Inc. | Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry |
| US12312437B2 (en) | 2016-04-15 | 2025-05-27 | Beckman Coulter, Inc. | Photoactive macromolecules and uses thereof |
| US12344643B2 (en) | 2016-12-07 | 2025-07-01 | The University Of Chicago | Compositions and methods for inhibition of FOXP3 |
| US12441775B2 (en) | 2022-08-29 | 2025-10-14 | Dana-Farber Cancer Institute, Inc. | BCL-W polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
| USRE38827E1 (en) | 1994-07-27 | 2005-10-11 | 3M Innovative Properties Company | Adhesive sealant composition |
| JP4344404B2 (en) | 1996-02-09 | 2009-10-14 | アムジェン インコーポレイテッド | Composition comprising interleukin-1 inhibitor and controlled release polymer |
| US5747639A (en)* | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| ATE406176T1 (en) | 1996-12-06 | 2008-09-15 | Amgen Inc | IL-1 INHIBITOR IN COMBINATION THERAPY FOR THE TREATMENT OF IL-1-MEDIATED DISEASES |
| US6743248B2 (en) | 1996-12-18 | 2004-06-01 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
| US20030191496A1 (en)* | 1997-03-12 | 2003-10-09 | Neomend, Inc. | Vascular sealing device with microwave antenna |
| US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
| US20040176801A1 (en)* | 1997-03-12 | 2004-09-09 | Neomend, Inc. | Pretreatment method for enhancing tissue adhesion |
| WO2001087925A2 (en)* | 2000-05-16 | 2001-11-22 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
| US6168784B1 (en) | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
| DK1411075T3 (en) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Process for Preparation of Polymer Conjugates |
| US6458147B1 (en) | 1998-11-06 | 2002-10-01 | Neomend, Inc. | Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue |
| US6994686B2 (en) | 1998-08-26 | 2006-02-07 | Neomend, Inc. | Systems for applying cross-linked mechanical barriers |
| ATE364654T1 (en) | 1998-08-28 | 2007-07-15 | Amylin Pharmaceuticals Inc | POLYAMIDE CHAINS OF PRECISE LENGTH AND THEIR CONJUGATES WITH PROTEINS |
| US6949114B2 (en) | 1998-11-06 | 2005-09-27 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US7279001B2 (en)* | 1998-11-06 | 2007-10-09 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US6830756B2 (en)* | 1998-11-06 | 2004-12-14 | Neomend, Inc. | Systems, methods, and compositions for achieving closure of vascular puncture sites |
| US6899889B1 (en)* | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
| US7008635B1 (en)* | 1999-09-10 | 2006-03-07 | Genzyme Corporation | Hydrogels for orthopedic repair |
| US7074878B1 (en)* | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| ES2327606T3 (en) | 2000-01-10 | 2009-11-02 | Maxygen Holdings Ltd | CONJUGATES OF G-CSF. |
| WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| TW593427B (en)* | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| US7053150B2 (en)* | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| YU48703A (en) | 2001-02-27 | 2006-05-25 | Maxygen Aps | New interferon beta-like molecules |
| EP2939696B1 (en) | 2001-10-18 | 2016-03-09 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
| WO2003044231A1 (en)* | 2001-11-23 | 2003-05-30 | Simon Fredriksson | Method and kit for proximity probing with multivalent proximity probes |
| GEP20074024B (en) | 2002-01-18 | 2007-01-10 | Biogen Idec Inc | Polyalkylene glycol comprising a radical for conjugation of biologically active compound |
| DK1517710T3 (en)* | 2002-06-21 | 2011-07-18 | Novo Nordisk Healthcare Ag | Pegylated factor VII glycoforms |
| US7034127B2 (en)* | 2002-07-02 | 2006-04-25 | Genzyme Corporation | Hydrophilic biopolymer-drug conjugates, their preparation and use |
| CN1312279C (en)* | 2002-11-07 | 2007-04-25 | 连云港新阳医药有限公司 | Method for preparing elspar modilfied by carbowax |
| ES2352337T5 (en)* | 2003-01-06 | 2017-08-11 | Nektar Therapeutics | Thiol-selective derivatives of a water soluble polymer |
| SI1596887T1 (en) | 2003-02-26 | 2022-05-31 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| TW200510454A (en) | 2003-04-15 | 2005-03-16 | Smithkline Beecham Corp | Conjugates comprising human IL-18 and substitution mutants thereof |
| US20040249119A1 (en)* | 2003-06-05 | 2004-12-09 | Fox Martin Edward | Novel mPEG propionaldehyde precursor |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| PL1656410T3 (en) | 2003-07-22 | 2010-08-31 | Nektar Therapeutics | Method for preparing functionalized polymers from polymer alcohols |
| KR20120073370A (en) | 2003-09-17 | 2012-07-04 | 넥타르 테라퓨틱스 | Multi-arm polymer prodrugs |
| JP4890253B2 (en)* | 2003-10-09 | 2012-03-07 | アンブレツクス・インコーポレイテツド | Azide or acetylene-terminated water-soluble polymer |
| EP1673387B1 (en) | 2003-10-10 | 2010-09-15 | Novo Nordisk A/S | Il-21 derivatives |
| US7524813B2 (en)* | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| EP2633866A3 (en) | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
| US8637650B2 (en) | 2003-11-05 | 2014-01-28 | Genovoxx Gmbh | Macromolecular nucleotide compounds and methods for using the same |
| MXPA06005732A (en)* | 2003-11-24 | 2006-08-17 | Neose Technologies Inc | Glycopegylated erythropoietin. |
| KR100580644B1 (en)* | 2004-02-16 | 2006-05-16 | 삼성전자주식회사 | Noncovalently Immobilized Biomolecules on Solid Substrates and Microarrays Prepared thereby |
| EP1725262B1 (en)* | 2004-03-15 | 2021-05-26 | Nektar Therapeutics | Polymer-based compositions and conjugates of hiv entry inhibitors |
| EP1735340A2 (en)* | 2004-03-17 | 2006-12-27 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| EP2359842A1 (en) | 2004-07-14 | 2011-08-24 | University of Utah Research Foundation | Netrin-related compositions and uses |
| EP1799713B1 (en) | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| WO2006047419A2 (en)* | 2004-10-25 | 2006-05-04 | Intezyne Technologies, Incorporated | Heterobifunctional poly(ethylene glycol) and uses thereof |
| EP1828224B1 (en) | 2004-12-22 | 2016-04-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
| US7365127B2 (en)* | 2005-02-04 | 2008-04-29 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
| EP1885403B1 (en) | 2005-04-12 | 2013-05-08 | Nektar Therapeutics | Poly(ethyleneglycol) conjugates of Lysostaphin |
| KR20080013878A (en) | 2005-04-18 | 2008-02-13 | 노보 노르디스크 에이/에스 | IL-21 variants |
| BRPI0609676A2 (en) | 2005-05-13 | 2011-10-18 | Lilly Co Eli | compound of pegylated glp-1, and use thereof |
| US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| ATE524509T1 (en) | 2005-07-18 | 2011-09-15 | Nektar Therapeutics | BRANCHED FUNCTIONALIZED POLYMERS USING BRANCHED POLYOLS AS CORE |
| EP1968644B1 (en) | 2005-12-16 | 2012-06-27 | Nektar Therapeutics | Polymer conjugates of glp-1 |
| US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
| JP5312050B2 (en) | 2006-02-21 | 2013-10-09 | ネクター セラピューティクス | Split-type degradable polymers and composites produced therefrom |
| US9101670B2 (en) | 2006-04-07 | 2015-08-11 | Nektar Therapeutics | Conjugates of an anti-TNF-α antibody |
| US8288339B2 (en) | 2006-04-20 | 2012-10-16 | Amgen Inc. | GLP-1 compounds |
| CA2650035C (en) | 2006-04-27 | 2015-02-03 | Intezyne Technologies, Inc. | Poly (ethylene glycol) containing chemically disparate endgroups |
| MX2008014685A (en) | 2006-05-24 | 2008-11-27 | Novo Nordisk Healthcare Ag | Factor ix analogues having prolonged in vivo half life. |
| WO2008002482A2 (en)* | 2006-06-23 | 2008-01-03 | Surmodics, Inc. | Hydrogel-based joint repair system and method |
| WO2008049920A2 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| US7935796B2 (en) | 2006-12-08 | 2011-05-03 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against ANGPTL3 |
| WO2008076933A2 (en) | 2006-12-14 | 2008-06-26 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| US8293214B2 (en) | 2006-12-19 | 2012-10-23 | Bracco Suisse S.A. | Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds |
| KR101160385B1 (en) | 2007-01-18 | 2012-07-10 | 일라이 릴리 앤드 캄파니 | PEGYLATED Aß FAB |
| ATE516814T1 (en) | 2007-02-02 | 2011-08-15 | Bristol Myers Squibb Co | 10FN3 DOMAIN FOR THE TREATMENT OF DISEASES ACCOMPANIED BY UNDESIRABLE ANGIOGENESIS |
| CN101361968B (en) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | Use of interleukin-22 in treating fatty liver |
| MX2010004400A (en) | 2007-10-23 | 2010-05-20 | Nektar Therapeutics | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom. |
| US20090123519A1 (en)* | 2007-11-12 | 2009-05-14 | Surmodics, Inc. | Swellable hydrogel matrix and methods |
| CN101903439A (en)* | 2007-11-12 | 2010-12-01 | 因特拉迪格姆公司 | Heterobifunctional polyethylene glycol reagents |
| US20090226531A1 (en)* | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
| NZ588989A (en) | 2008-04-21 | 2012-03-30 | Taigen Biotechnology Co Ltd | Heterocyclic compounds comprising pyrimidine, piperazine and amine. |
| US20110135623A1 (en)* | 2008-05-16 | 2011-06-09 | Nektar Therapeutics | Conjugates of a Cholinesterase Moiety and a Polymer |
| PE20091931A1 (en) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | MULTIVALENT FIBRONECTIN-BASED FRAME DOMAIN PROTEINS |
| AU2009282413B2 (en) | 2008-08-11 | 2014-07-17 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| US20110171164A1 (en)* | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| EP2340050A2 (en)* | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
| US20110171312A1 (en)* | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| EP2334333A1 (en)* | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
| EP2344199A1 (en)* | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Polymer conjugates of thymosin alpha 1 peptides |
| WO2010033224A1 (en)* | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
| EP2340046A2 (en)* | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of ziconotide peptides |
| EP2341942A1 (en) | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| WO2010033218A1 (en)* | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
| WO2010033204A2 (en)* | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of c-peptides |
| EP2334334A1 (en)* | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| EP2334337A1 (en)* | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
| EP2340045B1 (en) | 2008-09-19 | 2017-04-12 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
| WO2010056847A2 (en) | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| GB0823309D0 (en)* | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| US20110318322A1 (en) | 2009-01-12 | 2011-12-29 | Nektar Therapeutics | Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer |
| US8067201B2 (en)* | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
| DE102010049607A1 (en) | 2009-10-26 | 2011-06-30 | Becker, Claus, Prof., 76470 | Conjugates of nucleotides and methods for their use |
| CA2778678A1 (en) | 2009-10-30 | 2011-05-05 | Cns Therapeutics, Inc. | Improved neurturin molecules |
| AR079344A1 (en) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY |
| JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Oxyntomodulin peptide analogue |
| CN102161754B (en)* | 2010-02-13 | 2012-06-13 | 华中科技大学同济医学院附属协和医院 | Functional modification method for branched polyethylene glycol (PEG) derivative |
| WO2011107591A1 (en) | 2010-03-05 | 2011-09-09 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| US8980253B2 (en) | 2010-04-26 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| EP2563381B1 (en) | 2010-04-27 | 2017-08-09 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
| CA2797271C (en) | 2010-04-28 | 2021-05-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
| JP5991963B2 (en) | 2010-04-29 | 2016-09-14 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of valyl tRNA synthetase |
| JP6008838B2 (en) | 2010-04-29 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of asparaginyl tRNA synthetase |
| US9068177B2 (en) | 2010-04-29 | 2015-06-30 | Atyr Pharma, Inc | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
| EP2566495B1 (en) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
| EP2566496B1 (en) | 2010-05-03 | 2018-02-28 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
| EP2566515B1 (en) | 2010-05-03 | 2017-08-02 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
| CN102985103A (en) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
| EP2569331A1 (en) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptide inhibitors of vla4 |
| WO2011143482A2 (en) | 2010-05-14 | 2011-11-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| WO2011146410A2 (en) | 2010-05-17 | 2011-11-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
| CN103119055A (en) | 2010-05-17 | 2013-05-22 | 塞比克斯公司 | Pegylated C-Peptide |
| JP6023703B2 (en) | 2010-05-26 | 2016-11-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fibronectin based scaffold proteins with improved stability |
| CA2800281C (en) | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
| MX382876B (en) | 2010-07-30 | 2025-03-13 | Alcon Inc | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES. |
| AU2011293294B2 (en) | 2010-08-25 | 2016-03-24 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases |
| RU2441036C1 (en)* | 2010-09-30 | 2012-01-27 | Общество с ограниченной ответственностью Научно-производственное объединение "Перспектива" (ООО НПО "Перспектива") | Method of producing activated polyethylene oxide |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| CA3144697A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| AU2011332007C1 (en) | 2010-11-24 | 2017-03-02 | Lexicon Pharmaceuticals, Inc. | Antibodies to Notum Pectinacetylesterase |
| US20140371258A1 (en) | 2010-12-17 | 2014-12-18 | Nektar Therapeutics | Water-Soluble Polymer Conjugates of Topotecan |
| US10736969B2 (en) | 2010-12-21 | 2020-08-11 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| US20140088021A1 (en) | 2011-05-27 | 2014-03-27 | Nektar Therapeutics | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds |
| CN103687622A (en) | 2011-06-16 | 2014-03-26 | 香港科技大学 | Multiple vinyl sulfone containing molecules |
| KR20140054009A (en) | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | Relaxin fusion polypeptides and uses thereof |
| WO2013020079A2 (en) | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| CN104053670A (en) | 2011-10-31 | 2014-09-17 | 百时美施贵宝公司 | Fibronectin binding domains with reduced immunogenicity |
| CA2855770A1 (en) | 2011-11-17 | 2013-05-23 | Cebix Ab | Pegylated c-peptide |
| WO2013123432A2 (en) | 2012-02-16 | 2013-08-22 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| EP2838577B1 (en) | 2012-04-02 | 2019-02-27 | SurModics, Inc. | Hydrophilic polymeric coatings for medical articles with visualization moiety |
| WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| CN109503714A (en) | 2012-06-21 | 2019-03-22 | 索伦托治疗有限公司 | Antigen-binding proteins in conjunction with c-Met |
| EP2864358B1 (en) | 2012-06-22 | 2019-08-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
| US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
| WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
| EP3077008B1 (en) | 2013-12-06 | 2023-10-04 | Jie Han | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| MA39711A (en) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugates of an il-15 moiety and a polymer |
| US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| US10166273B2 (en) | 2014-08-12 | 2019-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein |
| AU2015305894A1 (en) | 2014-08-22 | 2017-04-06 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CXCR3 |
| SG11201701384XA (en) | 2014-10-14 | 2017-03-30 | Polytherics Ltd | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
| BR112017005760A2 (en)* | 2014-10-24 | 2017-12-12 | Polytherics Ltd | conjugates and conjugation reagents |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| JP7407511B2 (en) | 2015-10-08 | 2024-01-04 | ネクター セラピューティクス | Combination of IL-2Rβ selective agonist and long-acting IL-15 agonist |
| CN116333124A (en) | 2016-01-29 | 2023-06-27 | 索伦托药业有限公司 | Antigen-binding protein that binds to PD-L1 |
| CN109328069B (en) | 2016-04-15 | 2023-09-01 | 亿一生物医药开发(上海)有限公司 | Use of IL-22 in the treatment of necrotizing enterocolitis |
| CN109562167A (en) | 2016-08-09 | 2019-04-02 | 伊莱利利公司 | Combination therapy |
| WO2018172503A2 (en) | 2017-03-24 | 2018-09-27 | Basf Se | Liquid laundry detergent comprising modified saccharide or polysaccharide |
| CA3060410A1 (en) | 2017-05-15 | 2018-11-22 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
| US11485781B2 (en) | 2017-08-17 | 2022-11-01 | Massachusetts Institute Of Technology | Multiple specificity binders of CXC chemokines |
| WO2019063958A1 (en) | 2017-09-27 | 2019-04-04 | The University Of York | Bioconjugation of polypeptides |
| MX2020005041A (en) | 2017-11-21 | 2020-10-12 | Univ Leland Stanford Junior | Partial agonists of interleukin-2. |
| KR102167755B1 (en) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | Fragmented GRS polypeptide, mutants thereof and use thereof |
| US12377294B2 (en) | 2018-08-28 | 2025-08-05 | Ambrx, Inc. | Anti-CD3 antibody folate bioconjugates and their uses |
| MX2021006259A (en) | 2018-11-30 | 2021-09-30 | Eirgen Pharma Ltd | Oxyntomodulin peptide analog formulations. |
| US11235032B2 (en) | 2019-01-23 | 2022-02-01 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| US11191709B2 (en) | 2019-04-26 | 2021-12-07 | The Procter & Gamble Company | Reduction of tooth staining derived from cationic antimicrobials |
| US11491205B2 (en) | 2020-01-14 | 2022-11-08 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| WO2024241086A1 (en) | 2023-05-24 | 2024-11-28 | Ambrx, Inc. | Pegylated bovine interferon lambda and methods of use thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784524A (en)* | 1971-06-25 | 1974-01-08 | Grace W R & Co | Urethane/thioether-containing polyene composition and the reaction product thereof |
| US4002531A (en)* | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4066581A (en)* | 1976-02-26 | 1978-01-03 | Behringwerke Aktiengesellschaft | Process for producing a bond between polyvinylene glycol and a substance containing primary amino groups |
| US4066638A (en)* | 1973-10-17 | 1978-01-03 | Hoechst Aktiengesellschaft | Water-soluble fiber reactive phenyl-azo-naphthyl dyestuffs containing two sulfo groups in the phenyl moiety |
| US4101380A (en)* | 1975-06-12 | 1978-07-18 | Research Products Rehovot Ltd. | Process for the cross-linking of proteins |
| US4134887A (en)* | 1973-10-17 | 1979-01-16 | Hoechst Aktiengesellschaft | Phenyl-azo-phenyl dyestuffs |
| US4179387A (en)* | 1974-03-12 | 1979-12-18 | Fuji Photo Film Co., Ltd. | Process for producing magnetic FE oxide |
| US4179337A (en)* | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4228019A (en)* | 1978-06-19 | 1980-10-14 | Texaco Development Corp. | Secondary recovery process |
| US4296097A (en)* | 1979-02-27 | 1981-10-20 | Lee Weng Y | Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor |
| US4356166A (en)* | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
| US4424311A (en)* | 1981-07-01 | 1984-01-03 | Toray Industries, Incorporated | Antithrombogenic biomedical material |
| US4430260A (en)* | 1979-02-27 | 1984-02-07 | Lee Weng Y | Penicillin-polyvinyl alcohol conjugate and process of preparation |
| US4473693A (en)* | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
| US4559179A (en)* | 1983-04-12 | 1985-12-17 | Daikan Kogyo Co., Ltd. | Fluorine-containing vinyl compound |
| US4616644A (en)* | 1985-06-14 | 1986-10-14 | Johnson & Johnson Products, Inc. | Hemostatic adhesive bandage |
| WO1987000056A1 (en)* | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4670417A (en)* | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4677027A (en)* | 1984-10-19 | 1987-06-30 | Exploaterings Ab T.B.F. | Polymer coated particles having immobilized metal ions on the surfaces thereof |
| US4696980A (en)* | 1984-05-17 | 1987-09-29 | Jerker Porath | Sulfone activated thioether adsorbents for the separation of proteins and the like |
| EP0247860A2 (en)* | 1986-05-29 | 1987-12-02 | Cetus Oncology Corporation | Tumor necrosis factor formulation and its preparation |
| US4766106A (en)* | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4791192A (en)* | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4845024A (en)* | 1986-08-23 | 1989-07-04 | Agfa Gevaert Aktiengessellschaft | Hardeners for proteins, a binder layer hardened therewith and a photographic recording material containing such a layer |
| US4871785A (en)* | 1986-08-13 | 1989-10-03 | Michael Froix | Clouding-resistant contact lens compositions |
| US4883864A (en)* | 1985-09-06 | 1989-11-28 | Minnesota Mining And Manufacturing Company | Modified collagen compound and method of preparation |
| US4902502A (en)* | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4917888A (en)* | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| WO1990004606A1 (en)* | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | A process for fractionating polyethylene glycol (peg)-protein adducts and an adduct of peg and granulocyte-macrophage colony stimulating factor |
| WO1990004650A1 (en)* | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | A purification process for covalently bound dna/protein complexes |
| WO1990004384A1 (en)* | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | Liposomes |
| US4931544A (en)* | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
| US4931579A (en)* | 1986-10-10 | 1990-06-05 | Miles Inc. | Indicators for the detection of thiol groups |
| US4965112A (en)* | 1988-03-08 | 1990-10-23 | Stichting Voor De Technische Wetenschappen | Method for applying a blood-compatible coating to polyether-urethane moulded articles and the polymether-urethane moulded articles coated in this way |
| US4973493A (en)* | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
| WO1990015628A1 (en)* | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
| US4983494A (en)* | 1985-10-16 | 1991-01-08 | Fuji Photo Film Co., Ltd. | Image forming process including heating step |
| WO1991007190A1 (en)* | 1989-11-22 | 1991-05-30 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute |
| US5080891A (en)* | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5089261A (en)* | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| WO1992004384A1 (en)* | 1990-08-31 | 1992-03-19 | Regents Of The University Of Minnesota | Polyethylene glycol derivatives for solid-phase applications |
| WO1992007006A1 (en)* | 1990-10-22 | 1992-04-30 | Berol Nobel Ab | A solid surface coated with a hydrophilic outer layer with covalently bonded biopolymers, a method of making such a surface, and a conjugate therefor |
| WO1992006678A1 (en)* | 1990-10-15 | 1992-04-30 | Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
| US5122614A (en)* | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| WO1992013095A1 (en)* | 1991-01-18 | 1992-08-06 | Synergen, Inc. | Methods for treating tumor necrosis factor mediated diseases |
| WO1992016555A1 (en)* | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| WO1992016292A1 (en)* | 1991-03-22 | 1992-10-01 | Kem-En-Tec A/S | Adsorption matrices |
| WO1992016221A1 (en)* | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
| US5153265A (en)* | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US5162430A (en)* | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5171264A (en)* | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| WO1993001498A1 (en)* | 1991-07-04 | 1993-01-21 | Immunodex K/S | Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone |
| EP0622394A1 (en)* | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2850058A1 (en)* | 1978-11-18 | 1980-05-29 | Bayer Ag | POLYAETHER DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
| US4241199A (en)* | 1979-09-18 | 1980-12-23 | Union Carbide Corporation | Novel polyester diols |
| US4280979A (en)* | 1979-09-18 | 1981-07-28 | Union Carbide Corporation | Copolymers, compositions, and articles, and methods for making same |
| DK130991D0 (en)* | 1991-07-04 | 1991-07-04 | Immunodex K S | POLYMER CONJUGATES |
| US5414135A (en) | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784524A (en)* | 1971-06-25 | 1974-01-08 | Grace W R & Co | Urethane/thioether-containing polyene composition and the reaction product thereof |
| US4179337A (en)* | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4066638A (en)* | 1973-10-17 | 1978-01-03 | Hoechst Aktiengesellschaft | Water-soluble fiber reactive phenyl-azo-naphthyl dyestuffs containing two sulfo groups in the phenyl moiety |
| US4134887A (en)* | 1973-10-17 | 1979-01-16 | Hoechst Aktiengesellschaft | Phenyl-azo-phenyl dyestuffs |
| US4179387A (en)* | 1974-03-12 | 1979-12-18 | Fuji Photo Film Co., Ltd. | Process for producing magnetic FE oxide |
| US4101380A (en)* | 1975-06-12 | 1978-07-18 | Research Products Rehovot Ltd. | Process for the cross-linking of proteins |
| US4002531A (en)* | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4066581A (en)* | 1976-02-26 | 1978-01-03 | Behringwerke Aktiengesellschaft | Process for producing a bond between polyvinylene glycol and a substance containing primary amino groups |
| US4228019A (en)* | 1978-06-19 | 1980-10-14 | Texaco Development Corp. | Secondary recovery process |
| US4473693A (en)* | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
| US4356166A (en)* | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
| US4430260A (en)* | 1979-02-27 | 1984-02-07 | Lee Weng Y | Penicillin-polyvinyl alcohol conjugate and process of preparation |
| US4296097A (en)* | 1979-02-27 | 1981-10-20 | Lee Weng Y | Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor |
| US4424311A (en)* | 1981-07-01 | 1984-01-03 | Toray Industries, Incorporated | Antithrombogenic biomedical material |
| US4973493A (en)* | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
| US4559179A (en)* | 1983-04-12 | 1985-12-17 | Daikan Kogyo Co., Ltd. | Fluorine-containing vinyl compound |
| US4696980A (en)* | 1984-05-17 | 1987-09-29 | Jerker Porath | Sulfone activated thioether adsorbents for the separation of proteins and the like |
| US4677027A (en)* | 1984-10-19 | 1987-06-30 | Exploaterings Ab T.B.F. | Polymer coated particles having immobilized metal ions on the surfaces thereof |
| US4616644A (en)* | 1985-06-14 | 1986-10-14 | Johnson & Johnson Products, Inc. | Hemostatic adhesive bandage |
| US4670417A (en)* | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987000056A1 (en)* | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en)* | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4917888A (en)* | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4883864A (en)* | 1985-09-06 | 1989-11-28 | Minnesota Mining And Manufacturing Company | Modified collagen compound and method of preparation |
| US4983494A (en)* | 1985-10-16 | 1991-01-08 | Fuji Photo Film Co., Ltd. | Image forming process including heating step |
| EP0247860A2 (en)* | 1986-05-29 | 1987-12-02 | Cetus Oncology Corporation | Tumor necrosis factor formulation and its preparation |
| US4791192A (en)* | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4871785A (en)* | 1986-08-13 | 1989-10-03 | Michael Froix | Clouding-resistant contact lens compositions |
| US4845024A (en)* | 1986-08-23 | 1989-07-04 | Agfa Gevaert Aktiengessellschaft | Hardeners for proteins, a binder layer hardened therewith and a photographic recording material containing such a layer |
| US4931544A (en)* | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
| US4931579A (en)* | 1986-10-10 | 1990-06-05 | Miles Inc. | Indicators for the detection of thiol groups |
| US5080891A (en)* | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5153265A (en)* | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US4965112A (en)* | 1988-03-08 | 1990-10-23 | Stichting Voor De Technische Wetenschappen | Method for applying a blood-compatible coating to polyether-urethane moulded articles and the polymether-urethane moulded articles coated in this way |
| WO1990004384A1 (en)* | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | Liposomes |
| WO1990004650A1 (en)* | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | A purification process for covalently bound dna/protein complexes |
| WO1990004606A1 (en)* | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | A process for fractionating polyethylene glycol (peg)-protein adducts and an adduct of peg and granulocyte-macrophage colony stimulating factor |
| US5162430A (en)* | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US4902502A (en)* | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en)* | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5122614A (en)* | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| WO1990015628A1 (en)* | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
| WO1991007190A1 (en)* | 1989-11-22 | 1991-05-30 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute |
| US5171264A (en)* | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| WO1992004384A1 (en)* | 1990-08-31 | 1992-03-19 | Regents Of The University Of Minnesota | Polyethylene glycol derivatives for solid-phase applications |
| WO1992006678A1 (en)* | 1990-10-15 | 1992-04-30 | Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
| WO1992007006A1 (en)* | 1990-10-22 | 1992-04-30 | Berol Nobel Ab | A solid surface coated with a hydrophilic outer layer with covalently bonded biopolymers, a method of making such a surface, and a conjugate therefor |
| WO1992013095A1 (en)* | 1991-01-18 | 1992-08-06 | Synergen, Inc. | Methods for treating tumor necrosis factor mediated diseases |
| WO1992016221A1 (en)* | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
| WO1992016555A1 (en)* | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| WO1992016292A1 (en)* | 1991-03-22 | 1992-10-01 | Kem-En-Tec A/S | Adsorption matrices |
| WO1993001498A1 (en)* | 1991-07-04 | 1993-01-21 | Immunodex K/S | Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone |
| EP0622394A1 (en)* | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use |
| Title |
|---|
| CA95: 33396 vol. 95 (1981) Minamizono et al. DT3002724.* |
| Woghiren, et al., Protected Thiol Polyethylene Glycol: A New Activated Polymer For Reversible Protein Modification, Bioconjugate Chem. 1993, vol. 4, No. 5, pp. 314 318.* |
| Woghiren, et al., Protected Thiol-Polyethylene Glycol: A New Activated Polymer For Reversible Protein Modification, Bioconjugate Chem. 1993, vol. 4, No. 5, pp. 314-318. |
| Yoshinaga et al., Effects of Coupling Chemistry on the Activity of Poly(ethylene glycol) Modifified Alkaline Phosphatase, Journal of Bioactive and Compatible Polymers, Jan., 1989, vol. 4, pp. 17 24.* |
| Yoshinaga et al., Effects of Coupling Chemistry on the Activity of Poly(ethylene glycol)-Modifified Alkaline Phosphatase, Journal of Bioactive and Compatible Polymers, Jan., 1989, vol. 4, pp. 17-24. |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143866A (en)* | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
| US20030190304A1 (en)* | 1990-04-06 | 2003-10-09 | Amgen Inc. | Pegylation reagents and compounds formed therewith |
| US6552170B1 (en)* | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US8663629B2 (en) | 1994-01-11 | 2014-03-04 | Dyax Corp. | Kallikrein-binding “kunitz domain” proteins and analogues thereof |
| US8137989B2 (en) | 1994-03-18 | 2012-03-20 | Cytimmune Sciences, Inc. | Method for delivering a cytokine using a colloidal metal |
| EP0758906A1 (en)* | 1994-06-14 | 1997-02-26 | Tadahiko Kohno | Pegylation reagents and compounds formed therewith |
| US5672662A (en)* | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6989147B2 (en) | 1996-07-09 | 2006-01-24 | Amgen Inc. | Truncated soluble tumor necrosis factor type-I and type-II receptors |
| US7732587B2 (en) | 1996-07-09 | 2010-06-08 | Amgen Inc. | Nucleic acids encoding truncated soluble tumor necrosis factor |
| US20050250696A1 (en)* | 1996-07-09 | 2005-11-10 | Fisher Eric F | Truncated soluble tumor necrosis factor type-I and type-II receptors |
| US7605232B2 (en) | 1996-09-23 | 2009-10-20 | Incept Llc | Hydrogels for protein concentration |
| US20100069613A1 (en)* | 1996-09-23 | 2010-03-18 | Incept Llc | Implantable materials and compositions |
| US20020114775A1 (en)* | 1996-09-23 | 2002-08-22 | Incept Llc | Crosslinking agents and methods of use |
| US6887974B2 (en) | 1996-09-23 | 2005-05-03 | Incept Llc | Crosslinking agents and methods of use |
| US7057019B2 (en) | 1996-09-23 | 2006-06-06 | Incept Llc | Crosslinked albumin hydrogels |
| US8557535B2 (en) | 1996-09-23 | 2013-10-15 | Incept Llc | Methods for preparation of platelet rich plasma |
| US20070197776A1 (en)* | 1996-09-23 | 2007-08-23 | Incept Llc | Hydrogels for protein concentration |
| US20040002456A1 (en)* | 1996-09-23 | 2004-01-01 | Incept Llc | Methods and devices for preparing protein concentrates |
| US8003705B2 (en) | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
| US7211651B2 (en) | 1996-09-23 | 2007-05-01 | Incept Llc | Proteinaceous gels having visualization agents and methods of use thereof |
| US20030077272A1 (en)* | 1996-09-23 | 2003-04-24 | Incept Llc | Proteinaceous gels having visualization agents and methods of use thereof |
| US20080260802A1 (en)* | 1996-09-23 | 2008-10-23 | Sawhney Amarpreet S | Biocompatible hydrogels made with small molecule precursors |
| US6072040A (en)* | 1996-10-15 | 2000-06-06 | Medical Analysis Systems, Inc. | Stabilized conjugates of uncomplexed subunits of multimeric proteins |
| US6491923B1 (en) | 1996-10-15 | 2002-12-10 | Ivan E. Modrovich | Stabilized conjugates of uncomplexed subunits of multimeric proteins |
| US6306820B1 (en) | 1996-12-06 | 2001-10-23 | Amgen Inc. | Combination therapy using a TNF binding protein for treating TNF-mediated diseases |
| WO1998051336A1 (en)* | 1997-05-15 | 1998-11-19 | Theratech, Inc. | Targeted delivery to t lymphocytes |
| US6284246B1 (en) | 1997-07-30 | 2001-09-04 | The Procter & Gamble Co. | Modified polypeptides with high activity and reduced allergenicity |
| US6693083B2 (en) | 1997-08-05 | 2004-02-17 | Watson Pharmaceuticals, Inc. | Conjugates targeted to the interleukin-2 receptor |
| US6129928A (en)* | 1997-09-05 | 2000-10-10 | Icet, Inc. | Biomimetic calcium phosphate implant coatings and methods for making the same |
| US7790167B2 (en) | 1997-11-10 | 2010-09-07 | Cyt Immune Sciences, Inc. | Methods and compositions for enhancing immune response and for the production of in vitro Mabs |
| US20030180252A1 (en)* | 1997-11-10 | 2003-09-25 | Lawrence Tamarkin | Methods and compositions for enhancing immune response and for the production of in vitro Mabs |
| US6066673A (en)* | 1998-03-12 | 2000-05-23 | The Procter & Gamble Company | Enzyme inhibitors |
| US6569663B1 (en) | 1998-03-26 | 2003-05-27 | The Procter & Gamble Company | Serine protease variants having amino acid substitutions |
| US6495136B1 (en) | 1998-03-26 | 2002-12-17 | The Procter & Gamble Company | Proteases having modified amino acid sequences conjugated to addition moieties |
| US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
| US20040033264A1 (en)* | 1998-08-14 | 2004-02-19 | Incept Llc | Composite hydrogel drug delivery systems |
| US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| US20080279944A1 (en)* | 1998-08-14 | 2008-11-13 | Incept Llc | Composite hydrogel drug delivery systems |
| US9254267B2 (en) | 1998-08-14 | 2016-02-09 | Incept, Llc | Composite hydrogel drug delivery systems |
| US7413752B2 (en) | 1998-08-14 | 2008-08-19 | Incept Llc | Composite hydrogel drug delivery systems |
| US20080181944A1 (en)* | 1998-09-08 | 2008-07-31 | Alza Corporation | Dosage Form Comprising Therapeutic Formulation |
| US20090130204A1 (en)* | 1998-09-08 | 2009-05-21 | Encinal Pharmaceutical Investment Inc. | Dosage Form Comprising Therapeutic Formulation |
| US20030157163A1 (en)* | 1998-09-08 | 2003-08-21 | Liang-Chang Dong | Dosage form comprising therapeutic formulation |
| US20100159002A1 (en)* | 1998-09-08 | 2010-06-24 | Liang-Chang Dong | Dosage form comprising therapeutic formulation |
| US6410017B1 (en) | 1998-09-22 | 2002-06-25 | The Procter & Gamble Company | Personal care compositions containing active proteins tethered to a water insoluble substrate |
| US20040087778A1 (en)* | 1998-10-23 | 2004-05-06 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7186810B2 (en) | 1998-10-23 | 2007-03-06 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20070160572A1 (en)* | 1998-11-10 | 2007-07-12 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US20040023842A1 (en)* | 1998-12-04 | 2004-02-05 | Incept | Biocompatible crosslinked polymers |
| US8535705B2 (en) | 1998-12-04 | 2013-09-17 | Incept, Llc | Biocompatible polymers and hydrogels and methods of use |
| US20030162841A1 (en)* | 1998-12-04 | 2003-08-28 | Incept | Biocompatible crosslinked polymers |
| US7670605B2 (en) | 1999-02-01 | 2010-03-02 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| US7744912B1 (en) | 1999-02-01 | 2010-06-29 | Eidgenossische Technische Hochschule Zurich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
| US20060127352A1 (en)* | 1999-02-01 | 2006-06-15 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| US20090098083A1 (en)* | 1999-02-01 | 2009-04-16 | Hubbell Jeffrey A | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| US7413739B2 (en) | 1999-02-01 | 2008-08-19 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| WO2000078285A1 (en)* | 1999-06-18 | 2000-12-28 | University Of Medicine And Dentistry Of New Jersey | Controlled release of therapeutics by in-situ entrapment by matrix cross-linking |
| US6586223B1 (en) | 1999-07-22 | 2003-07-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid substitutions in defined epitope regions |
| US6586224B1 (en) | 1999-07-22 | 2003-07-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions |
| US6566115B1 (en) | 1999-07-22 | 2003-05-20 | The Procter & Gamble Company | Protease conjugates having sterically protected clip sites |
| US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
| US6303119B1 (en) | 1999-09-22 | 2001-10-16 | The Procter & Gamble Company | Personal care compositions containing subtilisin enzymes bound to water insoluble substrates |
| US6818435B2 (en) | 2000-05-15 | 2004-11-16 | Tecan Trading Ag | Microfluidics devices and methods for performing cell based assays |
| US20030220245A1 (en)* | 2000-06-02 | 2003-11-27 | Hubbell Jeffrey A | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds |
| US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| US20050089970A1 (en)* | 2000-07-12 | 2005-04-28 | Bradburne James A. | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| US20060233747A1 (en)* | 2000-09-08 | 2006-10-19 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| US20030191291A1 (en)* | 2000-09-08 | 2003-10-09 | Kochendoerfer Gerd G. | Synthetic erythropoiesis stimulating proteins |
| US7132475B2 (en) | 2000-10-19 | 2006-11-07 | Ecole Polytechnique Federale De Lausanne | Block copolymers for multifunctional self-assembled systems |
| US20030059906A1 (en)* | 2000-10-19 | 2003-03-27 | Hubbell Jeffrey A. | Block copolymers for multifunctional self-assembled systems |
| US20040185103A1 (en)* | 2000-10-31 | 2004-09-23 | Danny Lewis | Methods and compositions for enhanced delivery of bioactive molecules |
| EP2316490A2 (en) | 2000-10-31 | 2011-05-04 | PR Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| US6706289B2 (en) | 2000-10-31 | 2004-03-16 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| US20030044468A1 (en)* | 2001-03-20 | 2003-03-06 | Francesco Cellesi | Two-phase processing of thermosensitive polymers for use as biomaterials |
| US6538104B2 (en) | 2001-04-27 | 2003-03-25 | Medical Analysis Systems, Inc. | Stabilization of cardiac troponin I subunits and complexes |
| US6989436B2 (en) | 2001-04-27 | 2006-01-24 | Medical Analysis Systems, Inc. | Stabilization of cardiac troponin I subunits and complexes |
| US20030176638A1 (en)* | 2001-04-27 | 2003-09-18 | Medical Analysis Systems, Inc. | Stabilization of cardiac troponin I subunits and complexes |
| US20070231408A1 (en)* | 2001-04-30 | 2007-10-04 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US8785202B2 (en) | 2001-04-30 | 2014-07-22 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| USRE42524E1 (en) | 2001-04-30 | 2011-07-05 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US20100143298A1 (en)* | 2001-04-30 | 2010-06-10 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US20040077835A1 (en)* | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
| WO2003018665A1 (en)* | 2001-08-22 | 2003-03-06 | Bioartificial Gel Technologies Inc. | Process for the preparation of activated polyethylene glycols |
| US7125558B2 (en) | 2001-08-22 | 2006-10-24 | Bioartificial Gel Technologies Inc, | Process for the preparation of activated polyethylene glycols |
| EP2305313A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| EP2279755A2 (en) | 2001-10-10 | 2011-02-02 | BioGeneriX AG | Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF) |
| US8716239B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF |
| EP2305314A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of antibodies |
| US8716240B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| EP2305311A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Glycoconjugation of peptides |
| EP2042196A2 (en) | 2001-10-10 | 2009-04-01 | Neose Technologies, Inc. | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| EP2305312A2 (en) | 2001-10-10 | 2011-04-06 | BioGeneriX AG | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| EP2298354A2 (en) | 2001-10-10 | 2011-03-23 | BioGeneriX AG | Remodelling and glycoconjugation of interferon-beta |
| EP2080525A1 (en) | 2001-10-10 | 2009-07-22 | BioGeneriX AG | Remodeling and Glycoconjugation of Peptides |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US8076292B2 (en) | 2001-10-10 | 2011-12-13 | Novo Nordisk A/S | Factor VIII: remodeling and glycoconjugation of factor VIII |
| EP2322229A2 (en) | 2001-10-10 | 2011-05-18 | Novo Nordisk A/S | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| EP2279754A2 (en) | 2001-10-10 | 2011-02-02 | BioGeneriX AG | Remodelling and glycoconjugation of human growth hormone (hGH) |
| EP2279753A2 (en) | 2001-10-10 | 2011-02-02 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
| US20030179692A1 (en)* | 2002-03-19 | 2003-09-25 | Yoshitaka Ohotomo | Storage medium |
| US20100034769A1 (en)* | 2002-03-22 | 2010-02-11 | Kuros Biosurgery, AG | Compositions for tissue augmentation |
| US8282912B2 (en) | 2002-03-22 | 2012-10-09 | Kuros Biosurgery, AG | Compositions for tissue augmentation |
| US20110086801A1 (en)* | 2002-06-07 | 2011-04-14 | Dyax Corp. | Prevention and reduction of blood loss |
| US8710007B2 (en) | 2002-06-07 | 2014-04-29 | Dyax Corp. | Prevention and reduction of blood loss |
| US10245307B2 (en) | 2002-06-07 | 2019-04-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US9114144B2 (en) | 2002-06-07 | 2015-08-25 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US9480733B2 (en) | 2002-06-07 | 2016-11-01 | Dyax Corp. | Prevention and reduction of blood loss |
| US11344610B2 (en) | 2002-06-07 | 2022-05-31 | Takeda Pharmaceutical Company Limited | Prevention and reduction of blood loss |
| US8053410B2 (en) | 2002-06-21 | 2011-11-08 | Novo Nordisk Health Care A/G | Pegylated factor VII glycoforms |
| US20040136956A1 (en)* | 2002-09-05 | 2004-07-15 | Barker Nicholas P. | Asialo-interferons and the treatment of liver cancer |
| US20040136955A1 (en)* | 2002-09-05 | 2004-07-15 | Barker Nicholas P | Modified asialo-interferons and uses thereof |
| US20090264600A1 (en)* | 2002-09-09 | 2009-10-22 | Nektar Therapeutics Al, Corporation | Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid |
| US9045494B2 (en) | 2002-09-09 | 2015-06-02 | Nektar Therapeutics | Orthoester compound |
| US8435504B2 (en) | 2002-09-09 | 2013-05-07 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US20050036978A1 (en)* | 2002-09-09 | 2005-02-17 | Antoni Kozlowski | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US7569214B2 (en) | 2002-09-09 | 2009-08-04 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US8182801B2 (en) | 2002-09-09 | 2012-05-22 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| US8784791B2 (en) | 2002-09-09 | 2014-07-22 | Nektar Therapeutics | Method for preparing water-soluble polymer derivatives bearing an N-succinimidyl ester |
| US20040136952A1 (en)* | 2002-12-26 | 2004-07-15 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US20040126361A1 (en)* | 2002-12-26 | 2004-07-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
| US20080058246A1 (en)* | 2002-12-26 | 2008-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US9125880B2 (en) | 2002-12-26 | 2015-09-08 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
| US8034900B2 (en) | 2002-12-30 | 2011-10-11 | Amylin Pharmaceuticals, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| US20060173159A1 (en)* | 2002-12-30 | 2006-08-03 | Miranda Leslie P | Water-soluble thioester and selenoester compounds and methods for making and using the same |
| AU2004204136B2 (en)* | 2003-01-06 | 2008-10-09 | Nektar Therapeutics | Thiol-selective water-soluble polmer derivatives |
| US8722032B2 (en) | 2003-01-06 | 2014-05-13 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| WO2004063250A1 (en)* | 2003-01-06 | 2004-07-29 | Nektar Therapeutics Al, Corporation | Thiol-selective water-soluble polmer derivatives |
| US9040658B2 (en) | 2003-01-06 | 2015-05-26 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| US20050014903A1 (en)* | 2003-01-06 | 2005-01-20 | Antoni Kozlowski | Thiol selective water soluble polymer derivatives |
| US20060014248A1 (en)* | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050221443A1 (en)* | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
| US20050048626A1 (en)* | 2003-01-06 | 2005-03-03 | Xencor, Inc. | BAFF variants and methods thereof |
| US9333267B2 (en) | 2003-01-06 | 2016-05-10 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| US20110034643A1 (en)* | 2003-01-06 | 2011-02-10 | Nektar Therapeutics | Thiol-Selective Water-Soluble Polymer Derivatives |
| US7910661B2 (en)* | 2003-01-06 | 2011-03-22 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| US8202517B2 (en) | 2003-03-05 | 2012-06-19 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20090181013A1 (en)* | 2003-03-05 | 2009-07-16 | Bookbinder Louis H | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20110008309A1 (en)* | 2003-03-05 | 2011-01-13 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20050260186A1 (en)* | 2003-03-05 | 2005-11-24 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7767429B2 (en) | 2003-03-05 | 2010-08-03 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US8431124B2 (en) | 2003-03-05 | 2013-04-30 | Halozyme, Inc. | Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP) |
| US8450470B2 (en) | 2003-03-05 | 2013-05-28 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20090253175A1 (en)* | 2003-03-05 | 2009-10-08 | Bookbinder Louis H | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20090181032A1 (en)* | 2003-03-05 | 2009-07-16 | Bookbinder Louis H | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20060104968A1 (en)* | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US8105586B2 (en) | 2003-03-05 | 2012-01-31 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20090123367A1 (en)* | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US20090214505A1 (en)* | 2003-03-05 | 2009-08-27 | Bookbinder Louis H | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20040268425A1 (en)* | 2003-03-05 | 2004-12-30 | Deliatroph Pharmaceuticals, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US8431380B2 (en) | 2003-03-05 | 2013-04-30 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20050130892A1 (en)* | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
| US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
| US8247381B2 (en) | 2003-03-14 | 2012-08-21 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
| US20080113410A1 (en)* | 2003-03-31 | 2008-05-15 | Xencor, Inc. | Method for Rational Pegylation of Proteins |
| US7587286B2 (en) | 2003-03-31 | 2009-09-08 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US20040249576A1 (en)* | 2003-03-31 | 2004-12-09 | Xencor | Methods for rational pegylation of proteins |
| US20050114037A1 (en)* | 2003-03-31 | 2005-05-26 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| EP2338333A2 (en) | 2003-04-09 | 2011-06-29 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| US8853161B2 (en) | 2003-04-09 | 2014-10-07 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
| US8063015B2 (en) | 2003-04-09 | 2011-11-22 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US9789196B2 (en) | 2003-04-11 | 2017-10-17 | Antriabio, Inc. | Site-specific insulin-polymer conjugates |
| EP2599502A2 (en) | 2003-04-11 | 2013-06-05 | PR Pharmaceuticals Inc. | Method for preparation of site-specific protein conjugates |
| US9040664B2 (en) | 2003-04-11 | 2015-05-26 | Antriabio, Inc. | Materials and methods for preparing protein-polymer conjugates |
| US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US20070041959A1 (en)* | 2003-08-29 | 2007-02-22 | Dyax Corp., A Delaware Corporation | Poly-pegylated protease inhibitors |
| US7550427B2 (en) | 2003-08-29 | 2009-06-23 | Dyax Corp. | Poly-pegylated protease inhibitors |
| US20050089515A1 (en)* | 2003-08-29 | 2005-04-28 | Dyax Corp. | Poly-pegylated protease inhibitors |
| EP2327723A2 (en) | 2003-10-10 | 2011-06-01 | Xencor, Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US7951614B2 (en) | 2003-12-02 | 2011-05-31 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US8632770B2 (en) | 2003-12-03 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated factor IX |
| US20100330060A1 (en)* | 2003-12-03 | 2010-12-30 | Novo Nordisk A/S | Glycopegylated factor ix |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US20050250678A1 (en)* | 2004-01-08 | 2005-11-10 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
| US7338933B2 (en) | 2004-01-08 | 2008-03-04 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
| US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
| US20050175584A1 (en)* | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
| US8906676B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| US8097702B2 (en) | 2004-02-02 | 2012-01-17 | Ambrx, Inc. | Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses |
| EP2327724A2 (en) | 2004-02-02 | 2011-06-01 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| US20080207877A1 (en)* | 2004-02-02 | 2008-08-28 | Ambrx, Inc. | Modified Human Four Helical Bundle Polypeptides and Their Uses |
| US20080146781A1 (en)* | 2004-02-02 | 2008-06-19 | Ambrx, Inc. | Modified Human Four Helical Bundle Polypeptides and Their Uses |
| US8778880B2 (en) | 2004-02-02 | 2014-07-15 | Ambrx, Inc. | Human growth hormone modified at position 35 |
| US8232371B2 (en) | 2004-02-02 | 2012-07-31 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
| US9260472B2 (en) | 2004-02-02 | 2016-02-16 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| US8907064B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| US20080097083A1 (en)* | 2004-02-02 | 2008-04-24 | Ambrx, Inc. | Modified Human Four Helical Bundle Polypeptides and Their Uses |
| US8119603B2 (en) | 2004-02-02 | 2012-02-21 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
| US20080114154A1 (en)* | 2004-02-02 | 2008-05-15 | Ambrx, Inc. | Modified Human Interferon Polypeptides and Their Uses |
| US9211315B2 (en) | 2004-03-05 | 2015-12-15 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7351787B2 (en) | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
| US20080139854A1 (en)* | 2004-03-05 | 2008-06-12 | Marie-Pierre Faure | Process for the preparation of activated polyethylene glycols |
| US8257699B2 (en) | 2004-03-05 | 2012-09-04 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20050228187A1 (en)* | 2004-03-05 | 2005-10-13 | Marie-Pierre Faure | Process for the preparation of activated polyethylene glycols |
| US8580252B2 (en) | 2004-03-05 | 2013-11-12 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7662908B2 (en) | 2004-03-05 | 2010-02-16 | Rba Pharma Inc. | Process for the preparation of activated polythylene glycols |
| US10016491B2 (en) | 2004-03-05 | 2018-07-10 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20050261232A1 (en)* | 2004-04-13 | 2005-11-24 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US8697065B2 (en) | 2004-04-13 | 2014-04-15 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US9393319B2 (en) | 2004-04-13 | 2016-07-19 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US8470315B2 (en) | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US20080085277A1 (en)* | 2004-06-18 | 2008-04-10 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| US7632924B2 (en) | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| US20060153860A1 (en)* | 2004-06-18 | 2006-07-13 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| WO2006009901A2 (en) | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| US8791066B2 (en) | 2004-07-13 | 2014-07-29 | Novo Nordisk A/S | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] |
| US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| US20100048871A1 (en)* | 2004-07-21 | 2010-02-25 | Ambrx, Inc. | Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids |
| US20060019347A1 (en)* | 2004-07-21 | 2006-01-26 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
| US8716225B2 (en) | 2004-09-27 | 2014-05-06 | Dyax Corp. | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US9757437B2 (en) | 2004-09-27 | 2017-09-12 | Dyax Corp. | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US10874714B2 (en) | 2004-10-29 | 2020-12-29 | 89Bio Ltd. | Method of treating fibroblast growth factor 21 (FGF-21) deficiency |
| EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US9200049B2 (en) | 2004-10-29 | 2015-12-01 | Novo Nordisk A/S | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
| EP2586456A1 (en) | 2004-10-29 | 2013-05-01 | BioGeneriX AG | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
| US8765883B2 (en) | 2004-12-21 | 2014-07-01 | Nektar Therapeutics | Stabilized polymeric thiol reagents |
| US8217123B2 (en) | 2004-12-21 | 2012-07-10 | Nektar Therapeutics | Stabilized polymeric thiol reagents |
| US7851565B2 (en) | 2004-12-21 | 2010-12-14 | Nektar Therapeutics | Stabilized polymeric thiol reagents |
| US9308274B2 (en) | 2004-12-21 | 2016-04-12 | Nektar Therapeutics | Stabilized polymeric thiol reagents |
| US8492488B2 (en) | 2004-12-21 | 2013-07-23 | Nektar Therapeutics | Stabilized polymeric thiol reagents |
| US20110112277A1 (en)* | 2004-12-21 | 2011-05-12 | Nektar Therapeutics | Stabilized Polymeric Thiol Reagents |
| US20060135586A1 (en)* | 2004-12-21 | 2006-06-22 | Antoni Kozlowski | Stabilized polymeric thiol reagents |
| US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
| US20100184140A1 (en)* | 2004-12-22 | 2010-07-22 | Ambrx, Inc. | Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof |
| US7883866B2 (en) | 2004-12-22 | 2011-02-08 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US7858344B2 (en) | 2004-12-22 | 2010-12-28 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| EP2284191A2 (en) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Process for the preparation of hGH |
| US7939496B2 (en) | 2004-12-22 | 2011-05-10 | Ambrx, Inc. | Modified human growth horomone polypeptides and their uses |
| US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
| US8143216B2 (en) | 2004-12-22 | 2012-03-27 | Ambrx, Inc. | Modified human growth hormone |
| US8178108B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
| US8163695B2 (en) | 2004-12-22 | 2012-04-24 | Ambrx | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| US20100173380A1 (en)* | 2004-12-22 | 2010-07-08 | Ambrx, Inc. | Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof |
| US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
| US7838265B2 (en) | 2004-12-22 | 2010-11-23 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US7846689B2 (en) | 2004-12-22 | 2010-12-07 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| US20100167347A1 (en)* | 2004-12-22 | 2010-07-01 | Ambrx, Inc. | Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof |
| US7959926B2 (en) | 2004-12-22 | 2011-06-14 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone mutants |
| US20100173379A1 (en)* | 2004-12-22 | 2010-07-08 | Ambrx, Inc. | Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof |
| US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
| US20060135427A1 (en)* | 2004-12-22 | 2006-06-22 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| US20100174054A1 (en)* | 2004-12-22 | 2010-07-08 | Ambrx, Inc. | Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof |
| US8178494B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Modified human growth hormone formulations with an increased serum half-life |
| US20110195899A1 (en)* | 2004-12-22 | 2011-08-11 | Ambrx, Inc. | Formulations of Human Growth Hormone Comprising a Non-Naturally Encoded Amino Acid |
| US7829310B2 (en) | 2004-12-22 | 2010-11-09 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
| EP2514757A2 (en) | 2005-01-10 | 2012-10-24 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| US9707252B2 (en) | 2005-02-09 | 2017-07-18 | Covidien Lp | Synthetic sealants |
| US20090030451A1 (en)* | 2005-02-09 | 2009-01-29 | Hadba Ahmad R | Synthetic Sealants |
| US20100196423A1 (en)* | 2005-02-23 | 2010-08-05 | Bookbinder Louis H | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| WO2006091871A1 (en) | 2005-02-23 | 2006-08-31 | Halozyme Therapeutics, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7846431B2 (en) | 2005-02-23 | 2010-12-07 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7829081B2 (en) | 2005-02-23 | 2010-11-09 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US10588983B2 (en) | 2005-02-23 | 2020-03-17 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP3045472A1 (en) | 2005-02-23 | 2016-07-20 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP3943501A1 (en) | 2005-02-23 | 2022-01-26 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP2279756A2 (en) | 2005-04-05 | 2011-02-02 | Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. | Method for shielding functional sites or epitopes on proteins |
| EP2314320A2 (en) | 2005-04-05 | 2011-04-27 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
| EP2386571A2 (en) | 2005-04-08 | 2011-11-16 | BioGeneriX AG | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US8907071B2 (en) | 2005-04-22 | 2014-12-09 | Amgen Inc. | Toxin peptide therapeutic agents |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| US20110045587A1 (en)* | 2005-04-22 | 2011-02-24 | Amegen Inc. | Toxin peptide therapeutic agents |
| US20070071764A1 (en)* | 2005-04-22 | 2007-03-29 | Sullivan John K | Toxin peptide therapeutic agents |
| US8404809B2 (en) | 2005-05-25 | 2013-03-26 | Novo Nordisk A/S | Glycopegylated factor IX |
| US20100081791A1 (en)* | 2005-05-25 | 2010-04-01 | Novo Nordisk A/S | Glycopegylated factor ix |
| EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
| US20080255026A1 (en)* | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| US9505867B2 (en) | 2005-05-31 | 2016-11-29 | Ecole Polytechmique Fédérale De Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
| US20100222407A1 (en)* | 2005-05-31 | 2010-09-02 | Tatiana Segura | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
| US20100135959A1 (en)* | 2005-06-03 | 2010-06-03 | Ambrx, Inc. | Human Interferon Molecules and Their Uses |
| US20080119640A1 (en)* | 2005-06-03 | 2008-05-22 | Ambrx, Inc. | Human Interferon Molecules and Their Uses |
| US20080132681A1 (en)* | 2005-06-03 | 2008-06-05 | Ambrx, Inc. | Human Interferon Molecules and Their Uses |
| US8093356B2 (en) | 2005-06-03 | 2012-01-10 | Ambrx, Inc. | Pegylated human interferon polypeptides |
| US20080108792A1 (en)* | 2005-06-03 | 2008-05-08 | Ambrx, Inc. | Human Interferon Molecules and Their Uses |
| US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
| US10188740B2 (en) | 2005-08-12 | 2019-01-29 | Amgen Inc. | Modified Fc molecules |
| US11266744B2 (en) | 2005-08-12 | 2022-03-08 | Amgen Inc. | Modified Fc molecules |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| EP2425860A1 (en) | 2005-08-12 | 2012-03-07 | Amgen Inc. | Modified Fc molecules |
| US7632823B2 (en) | 2005-08-18 | 2009-12-15 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
| US20080153745A1 (en)* | 2005-08-18 | 2008-06-26 | Ambrx, In. | Compositions of tRNA and uses thereof |
| US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
| US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
| US20090137736A1 (en)* | 2005-11-08 | 2009-05-28 | Ambrx, Inc. | Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides |
| US9488660B2 (en) | 2005-11-16 | 2016-11-08 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
| US20110144307A1 (en)* | 2005-11-16 | 2011-06-16 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
| US20080317670A1 (en)* | 2005-12-14 | 2008-12-25 | Ambrx, Inc. | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides |
| US20070137573A1 (en)* | 2005-12-21 | 2007-06-21 | Arnold Kholodenko | Apparatus for an optimized plasma chamber grounded electrode assembly |
| US20070196416A1 (en)* | 2006-01-18 | 2007-08-23 | Quest Pharmaceutical Services | Pharmaceutical compositions with enhanced stability |
| WO2007084460A2 (en) | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| US8840882B2 (en) | 2006-06-23 | 2014-09-23 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| US20080025964A1 (en)* | 2006-06-23 | 2008-01-31 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| WO2007149594A2 (en) | 2006-06-23 | 2007-12-27 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| US9192656B2 (en) | 2006-07-17 | 2015-11-24 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| US8298801B2 (en) | 2006-07-17 | 2012-10-30 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| US20080095755A1 (en)* | 2006-07-17 | 2008-04-24 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| US20110207914A1 (en)* | 2006-09-08 | 2011-08-25 | Ambrx, Inc. | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses |
| US20100160212A1 (en)* | 2006-09-08 | 2010-06-24 | Ambrx, Inc. | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses |
| US20100159586A1 (en)* | 2006-09-08 | 2010-06-24 | Ambrx, Inc. | Hybrid Suppressor tRNA for Vertebrate Cells |
| US8618257B2 (en) | 2006-09-08 | 2013-12-31 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
| US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
| US20100159585A1 (en)* | 2006-09-08 | 2010-06-24 | Ambrx, Inc. | Suppressor tRNA Transcription in Vertebrate Cells |
| US20080113411A1 (en)* | 2006-09-08 | 2008-05-15 | Ambrx, Inc. | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses |
| US7919591B2 (en) | 2006-09-08 | 2011-04-05 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| US8022186B2 (en) | 2006-09-08 | 2011-09-20 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| US20080113412A1 (en)* | 2006-09-08 | 2008-05-15 | Ambrx, Inc. | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses |
| US8053560B2 (en) | 2006-09-08 | 2011-11-08 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| EP2548967A2 (en) | 2006-09-21 | 2013-01-23 | The Regents of The University of California | Aldehyde tags, uses thereof in site-specific protein modification |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| WO2008060780A2 (en) | 2006-10-04 | 2008-05-22 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| US20090299044A1 (en)* | 2006-10-25 | 2009-12-03 | Sullivan John K | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression |
| US7803769B2 (en) | 2006-10-25 | 2010-09-28 | Amgen Inc. | OSK1 peptide analogs and pharmaceutical compositions |
| US7820623B2 (en) | 2006-10-25 | 2010-10-26 | Amgen Inc. | Conjugated toxin peptide therapeutic agents |
| US20090305399A1 (en)* | 2006-10-25 | 2009-12-10 | Sullivan John K | DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression |
| US8043829B2 (en) | 2006-10-25 | 2011-10-25 | Amgen Inc. | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression |
| US7825093B2 (en) | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
| US7834164B2 (en) | 2006-10-25 | 2010-11-16 | Amgen Inc. | DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression |
| US20090281028A1 (en)* | 2006-10-25 | 2009-11-12 | Sullivan John K | OSK1 peptide analogs and pharmaceutical compositions |
| US7910102B2 (en) | 2006-10-25 | 2011-03-22 | Amgen Inc. | Methods of using conjugated toxin peptide therapeutic agents |
| US8541608B2 (en) | 2006-11-30 | 2013-09-24 | Nektar Therapeutics | Method for preparing a polymer conjugate |
| US20100010194A1 (en)* | 2006-11-30 | 2010-01-14 | Nektar Therapeutics Al, Corporation | Method for Preparing a Polymer Conjugate |
| US8937180B2 (en) | 2006-11-30 | 2015-01-20 | Nektar Therapeutics | Method for preparing a polymer conjugate |
| US8354549B2 (en) | 2006-11-30 | 2013-01-15 | Nektar Therapeutics | Method for preparing a polymer conjugate |
| US8685417B2 (en) | 2006-12-20 | 2014-04-01 | Arkema, Inc. | Polymer encapsulation and/or binding |
| WO2008095063A1 (en) | 2007-01-31 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP2952522A1 (en) | 2007-01-31 | 2015-12-09 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| US20090227981A1 (en)* | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
| US20090227689A1 (en)* | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
| US8383365B2 (en) | 2007-03-30 | 2013-02-26 | Ambrx, Inc. | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives |
| US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
| US9517273B2 (en) | 2007-03-30 | 2016-12-13 | Ambrx, Inc. | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
| US20110172401A1 (en)* | 2007-03-30 | 2011-07-14 | Ambrx, Inc. | Modified FGF-21 Polypeptides and Their Uses |
| US11993637B2 (en) | 2007-03-30 | 2024-05-28 | Ambrx, Inc. | Modified FGF-21 polypeptides with non-naturally encoded amino acids |
| US9975936B2 (en) | 2007-03-30 | 2018-05-22 | Ambrx, Inc. | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
| US9079971B2 (en) | 2007-03-30 | 2015-07-14 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
| US10961291B2 (en) | 2007-03-30 | 2021-03-30 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
| US20080255045A1 (en)* | 2007-03-30 | 2008-10-16 | Ambrx, Inc. | Modified FGF-21 Polypeptides and Their Uses |
| US10377805B2 (en) | 2007-03-30 | 2019-08-13 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses |
| US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
| US8961947B2 (en) | 2007-04-13 | 2015-02-24 | Kuros Biosurgery Ag | Polymeric tissue sealant |
| US20080253987A1 (en)* | 2007-04-13 | 2008-10-16 | Kuros Biosurgery Ag | Polymeric tissue sealant |
| US9180222B2 (en) | 2007-04-13 | 2015-11-10 | Kuros Biosurgery Ag | Polymeric tissue sealant |
| US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| US20090208454A1 (en)* | 2007-05-02 | 2009-08-20 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| US8420779B2 (en) | 2007-05-22 | 2013-04-16 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| EP2738257A1 (en) | 2007-05-22 | 2014-06-04 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US20090118181A1 (en)* | 2007-05-22 | 2009-05-07 | Walker Kenneth W | Compositions and methods for producing bioactive fusion proteins |
| US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
| US20090000924A1 (en)* | 2007-06-29 | 2009-01-01 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
| US10251954B2 (en) | 2007-07-09 | 2019-04-09 | Incept, Llc | Hydrogel polymeric compositions and methods |
| US20090252781A1 (en)* | 2007-07-09 | 2009-10-08 | Incept Llc | Hydrogel polymeric compositions and methods |
| US9775906B2 (en) | 2007-07-09 | 2017-10-03 | Incept Llc | Hydrogel polymeric compositions and methods |
| US20090017097A1 (en)* | 2007-07-09 | 2009-01-15 | Sawhney Amarpreet S | Hydrogel polymeric compositions and methods |
| US11324828B2 (en) | 2007-07-09 | 2022-05-10 | Incept, Llc | Hydrogel polymeric compositions and methods |
| US9370485B2 (en) | 2007-07-09 | 2016-06-21 | Incept, Llc | Hydrogel polymeric compositions and methods |
| US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| US20110269942A1 (en)* | 2007-08-09 | 2011-11-03 | Daiichi Sankyo Company, Limited | Antibodies modified with hydrophobic molecule |
| US8067028B2 (en) | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
| US20090047349A1 (en)* | 2007-08-13 | 2009-02-19 | Confluent Surgical, Inc. | Drug delivery device |
| US20090075887A1 (en)* | 2007-08-21 | 2009-03-19 | Genzyme Corporation | Treatment with Kallikrein Inhibitors |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US20110014118A1 (en)* | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
| US20090104114A1 (en)* | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| US20090098101A1 (en)* | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
| US8697062B2 (en) | 2007-10-08 | 2014-04-15 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
| US8486663B2 (en) | 2007-11-08 | 2013-07-16 | Cytlmmune Sciences, Inc. | Compositions and methods for generating antibodies |
| US7960145B2 (en) | 2007-11-08 | 2011-06-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| US20090148908A1 (en)* | 2007-11-08 | 2009-06-11 | Paciotti Giulio F | Compositions and methods for generating antibodies |
| US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| EP2930182A1 (en) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| US20100298212A1 (en)* | 2007-11-20 | 2010-11-25 | Ambrx, Inc. | Modified Insulin Polypeptides and Their Uses |
| WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| US9938333B2 (en) | 2008-02-08 | 2018-04-10 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
| US9833498B2 (en) | 2008-03-06 | 2017-12-05 | Halozyme, Inc. | Methods of treatment of collagen-mediated diseases and conditions |
| US9775889B2 (en) | 2008-03-06 | 2017-10-03 | Halozyme, Inc. | Methods of treatment of cellulite |
| EP2662090A1 (en) | 2008-04-14 | 2013-11-13 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| EP3192525A1 (en) | 2008-04-14 | 2017-07-19 | Halozyme, Inc. | Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions |
| US10328130B2 (en) | 2008-04-14 | 2019-06-25 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| US8318154B2 (en) | 2008-04-28 | 2012-11-27 | Halozyme, Inc. | Super fast-acting insulin compositions |
| EP2705850A2 (en) | 2008-04-28 | 2014-03-12 | Halozyme, Inc. | Super fast-acting insulin compositions |
| US8618333B2 (en) | 2008-07-21 | 2013-12-31 | Polytherics Limited | Reagents and method for conjugating biological molecules |
| US8969626B2 (en) | 2008-07-21 | 2015-03-03 | Polytherics Limited | Reagents and method for conjugating biological molecules |
| US20110136723A1 (en)* | 2008-07-21 | 2011-06-09 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US9896412B2 (en) | 2008-07-21 | 2018-02-20 | Polytherics Limited | Reagents and method for conjugating biological molecules |
| WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| EP3225248A1 (en) | 2008-07-23 | 2017-10-04 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| US20100035812A1 (en)* | 2008-07-23 | 2010-02-11 | Ambrx, Inc. | Modified Bovine G-CSF Polypeptides And Their Uses |
| US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
| US20110195483A1 (en)* | 2008-09-26 | 2011-08-11 | Ambrx, Inc. | Non-Natural Amino Acid Replication-Dependent Microorganisms and Vaccines |
| US9121025B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| US20100093608A1 (en)* | 2008-09-26 | 2010-04-15 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US9121024B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| US9644014B2 (en) | 2008-09-26 | 2017-05-09 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US10428333B2 (en) | 2008-09-26 | 2019-10-01 | Ambrx Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| EP3216800A1 (en) | 2008-09-26 | 2017-09-13 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| US8569233B2 (en) | 2008-09-26 | 2013-10-29 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
| US9156899B2 (en) | 2008-09-26 | 2015-10-13 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
| US8029782B2 (en) | 2008-10-01 | 2011-10-04 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| US9579365B2 (en) | 2008-10-01 | 2017-02-28 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| US8216567B2 (en) | 2008-10-01 | 2012-07-10 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| US8628768B2 (en) | 2008-10-01 | 2014-01-14 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| US9006407B2 (en) | 2008-10-01 | 2015-04-14 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| US9271929B2 (en) | 2008-11-25 | 2016-03-01 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
| US10335499B2 (en) | 2008-11-25 | 2019-07-02 | École Polytechnique Fédérale De Lausanne (Epfl) | Block copolymers and uses thereof |
| US9284543B2 (en) | 2008-12-09 | 2016-03-15 | Halozyme, Inc. | Neutral active soluble truncated PH20 polypeptides and uses thereof |
| US8927249B2 (en) | 2008-12-09 | 2015-01-06 | Halozyme, Inc. | Extended soluble PH20 polypeptides and uses thereof |
| EP3037529A1 (en) | 2008-12-09 | 2016-06-29 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
| WO2010077297A1 (en) | 2008-12-09 | 2010-07-08 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
| US20100183625A1 (en)* | 2009-01-06 | 2010-07-22 | Dyax Corp. | Treatment of Mucositis with Kallikrein Inhibitors |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| US8563027B2 (en) | 2009-02-12 | 2013-10-22 | Incept, Llc | Drug delivery through hydrogel plugs |
| US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| US9415115B2 (en) | 2009-03-04 | 2016-08-16 | Polytherics Limited | Conjugated proteins and peptides |
| WO2010144629A1 (en) | 2009-06-09 | 2010-12-16 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| EP3266463A1 (en) | 2009-06-09 | 2018-01-10 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| EP2550958A1 (en) | 2009-08-05 | 2013-01-30 | Pieris AG | Controlled release formulations of lipocalin muteins |
| WO2011015634A2 (en) | 2009-08-05 | 2011-02-10 | Pieris Ag | Controlled release formulations of lipocalin muteins |
| US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| WO2011034604A2 (en) | 2009-09-17 | 2011-03-24 | Baxter Healthcare, S.A. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
| EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
| US20110200611A1 (en)* | 2010-01-06 | 2011-08-18 | Dyax Corp. | Plasma kallikrein binding proteins |
| US8822653B2 (en) | 2010-01-06 | 2014-09-02 | Dyax Corp. | Plasma kallikrein binding proteins |
| US10336832B2 (en) | 2010-01-06 | 2019-07-02 | Dyax Corp. | Methods of inhibiting plasma kallikrein in edema patient |
| US11505620B2 (en) | 2010-01-06 | 2022-11-22 | Takeda Pharmaceutical Company Limited | Methods of detecting plasma kallikrein |
| WO2012012300A2 (en) | 2010-07-20 | 2012-01-26 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| US9878046B2 (en) | 2010-07-20 | 2018-01-30 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| US10265410B2 (en) | 2010-07-20 | 2019-04-23 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
| US8735539B2 (en) | 2010-08-17 | 2014-05-27 | Ambrx, Inc. | Relaxin polypeptides comprising non-naturally encoded amino acids |
| US10702588B2 (en) | 2010-08-17 | 2020-07-07 | Ambrx, Inc. | Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain |
| US9452222B2 (en) | 2010-08-17 | 2016-09-27 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
| US11311605B2 (en) | 2010-08-17 | 2022-04-26 | Ambrx, Inc. | Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides |
| WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| EP4302783A2 (en) | 2010-08-17 | 2024-01-10 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US10253083B2 (en) | 2010-08-17 | 2019-04-09 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US10751391B2 (en) | 2010-08-17 | 2020-08-25 | Ambrx, Inc. | Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid |
| US11439710B2 (en) | 2010-08-17 | 2022-09-13 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
| US11786578B2 (en) | 2010-08-17 | 2023-10-17 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
| US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
| WO2012065181A2 (en) | 2010-11-12 | 2012-05-18 | Dana Farber Cancer Institute, Inc. | Cancer therapies and diagnostics |
| US11401346B2 (en) | 2011-01-06 | 2022-08-02 | Takeda Pharmaceutical Company Limited | Nucleic acids encoding plasma kallikrein binding proteins |
| US10370453B2 (en) | 2011-01-06 | 2019-08-06 | Dyax Corp. | Plasma kallikrein binding proteins |
| US9266964B2 (en) | 2011-01-06 | 2016-02-23 | Dyax Corp. | Method of treating hereditary angioedema using plasma kallikrein binding antibodies |
| EP2907504A1 (en) | 2011-02-08 | 2015-08-19 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| US9333244B2 (en) | 2011-02-08 | 2016-05-10 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| WO2012125973A2 (en) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
| WO2012174478A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| WO2012174480A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
| WO2013006706A1 (en) | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
| EP3088005A1 (en) | 2011-07-05 | 2016-11-02 | biOasis Technologies Inc | P97-antibody conjugates |
| US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
| WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| EP2915542A1 (en) | 2011-10-24 | 2015-09-09 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| WO2013063155A2 (en) | 2011-10-24 | 2013-05-02 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| US8846034B2 (en) | 2011-10-24 | 2014-09-30 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| US9458442B2 (en) | 2011-10-24 | 2016-10-04 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| US10905765B2 (en) | 2011-12-05 | 2021-02-02 | Incept, Llc | Medical organogel processes and compositions |
| US11890343B2 (en) | 2011-12-05 | 2024-02-06 | Incept, Llc | Medical organogel processes and compositions |
| US9205150B2 (en) | 2011-12-05 | 2015-12-08 | Incept, Llc | Medical organogel processes and compositions |
| US10077290B2 (en) | 2011-12-29 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized antiviral fusion helices |
| WO2013102211A2 (en) | 2011-12-29 | 2013-07-04 | Walensky Loren D | Stabilized antiviral fusion helices |
| US12054758B2 (en) | 2011-12-30 | 2024-08-06 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US11066656B2 (en) | 2011-12-30 | 2021-07-20 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12123035B2 (en) | 2011-12-30 | 2024-10-22 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US10865400B2 (en) | 2011-12-30 | 2020-12-15 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12110520B2 (en) | 2011-12-30 | 2024-10-08 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12018298B2 (en) | 2011-12-30 | 2024-06-25 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| EP3130347A1 (en) | 2011-12-30 | 2017-02-15 | Halozyme, Inc. | Ph20 polypeptide variants, formulations and uses thereof |
| US12037618B2 (en) | 2011-12-30 | 2024-07-16 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12195773B2 (en) | 2011-12-30 | 2025-01-14 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12104185B2 (en) | 2011-12-30 | 2024-10-01 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12371685B2 (en) | 2011-12-30 | 2025-07-29 | Halozyme, Inc. | PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof |
| US12049652B2 (en) | 2011-12-30 | 2024-07-30 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12264345B1 (en) | 2011-12-30 | 2025-04-01 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12060590B2 (en) | 2011-12-30 | 2024-08-13 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12077791B2 (en) | 2011-12-30 | 2024-09-03 | Halozyme, Inc. | PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof |
| US12152262B2 (en) | 2011-12-30 | 2024-11-26 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US11041149B2 (en) | 2011-12-30 | 2021-06-22 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US11952600B2 (en) | 2011-12-30 | 2024-04-09 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US9447401B2 (en) | 2011-12-30 | 2016-09-20 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12104184B2 (en) | 2011-12-30 | 2024-10-01 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US12091692B2 (en) | 2011-12-30 | 2024-09-17 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
| US9885072B2 (en) | 2012-03-30 | 2018-02-06 | The Board Of Regents Of The University Of Oklahoma | High molecular weight heparosan polymers and methods of production of use thereof |
| US8980608B2 (en) | 2012-03-30 | 2015-03-17 | The Board Of Regents Of The University Of Oklahoma | High molecular weight heparosan polymers and methods of production and use thereof |
| US10392642B2 (en) | 2012-03-30 | 2019-08-27 | The Board Of Regents Of The University Of Oklahoma | High molecular weight heparosan polymers and methods of production and use thereof |
| US10137104B2 (en) | 2012-04-04 | 2018-11-27 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and therapeutic agent |
| WO2013151774A1 (en) | 2012-04-04 | 2013-10-10 | Halozyme, Inc. | Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane |
| US9913822B2 (en) | 2012-04-04 | 2018-03-13 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and therapeutic agent |
| EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
| WO2013185115A1 (en) | 2012-06-08 | 2013-12-12 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| US11181754B2 (en) | 2012-08-27 | 2021-11-23 | Tangible Science, Llc | Contact lens with a hydrophilic layer |
| US10451896B2 (en) | 2012-08-27 | 2019-10-22 | Tangible Science, Llc | Contact lens with a hydrophilic layer |
| EP4074728A1 (en) | 2012-08-31 | 2022-10-19 | Sutro Biopharma, Inc. | Modified peptides comprising an azido group |
| WO2014036492A1 (en) | 2012-08-31 | 2014-03-06 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| EP3584255A1 (en) | 2012-08-31 | 2019-12-25 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US9579390B2 (en) | 2012-11-12 | 2017-02-28 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| US10314919B2 (en) | 2012-11-16 | 2019-06-11 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US11426465B2 (en) | 2012-11-16 | 2022-08-30 | Redwiid Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9605078B2 (en) | 2012-11-16 | 2017-03-28 | The Regents Of The University Of California | Pictet-Spengler ligation for protein chemical modification |
| US10888623B2 (en) | 2012-11-16 | 2021-01-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US9833515B2 (en) | 2012-11-16 | 2017-12-05 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| EP3907237A1 (en) | 2012-12-20 | 2021-11-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| WO2014099984A1 (en) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
| WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
| WO2014160438A1 (en) | 2013-03-13 | 2014-10-02 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| EP3572422A1 (en) | 2013-03-15 | 2019-11-27 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
| WO2014144148A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
| WO2014144768A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Bh4 stabilized peptides and uses thereof |
| US11046739B2 (en) | 2013-03-15 | 2021-06-29 | Dana-Farber Cancer Institute, Inc. | BH4 stabilized peptides and uses thereof |
| US10106590B2 (en) | 2013-03-15 | 2018-10-23 | Dana-Farber Cancer Institute, Inc. | BH4 stabilized peptides and uses thereof |
| US10308926B2 (en) | 2013-03-15 | 2019-06-04 | Dana-Farber Cancer Institute, Inc. | Stablized EZH2 peptides |
| US10087215B2 (en) | 2013-03-15 | 2018-10-02 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| WO2014151369A2 (en) | 2013-03-15 | 2014-09-25 | Dana-Farber Cancer Institute, Inc. | Stabilized ezh2 peptides |
| WO2015003167A1 (en) | 2013-07-03 | 2015-01-08 | Halozyme, Inc. | Thermally stable ph20 hyaluronidase variants and uses thereof |
| EP3336103A1 (en) | 2013-07-10 | 2018-06-20 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US10711106B2 (en) | 2013-07-25 | 2020-07-14 | The University Of Chicago | High aspect ratio nanofibril materials |
| WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| US11433628B2 (en) | 2013-11-15 | 2022-09-06 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
| US10330951B2 (en) | 2013-11-15 | 2019-06-25 | Tangible Science, Llc | Contact lens with a hydrophilic layer |
| US9310627B2 (en) | 2013-11-15 | 2016-04-12 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| EP4592275A2 (en) | 2013-11-27 | 2025-07-30 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| US11046785B2 (en) | 2014-03-27 | 2021-06-29 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| US12084515B2 (en) | 2014-03-27 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| US10358636B2 (en) | 2014-05-14 | 2019-07-23 | Stealth Biologics, Llc | Deimmunized lysostaphin and methods of use |
| US12104186B2 (en) | 2014-05-14 | 2024-10-01 | Insmed Incorporated | Deimmunized lysostaphin and methods of use |
| WO2015175774A1 (en) | 2014-05-14 | 2015-11-19 | Trustees Of Dartmouth College | Deimmunized lysostaphin and methods of use |
| US11091749B2 (en) | 2014-05-14 | 2021-08-17 | Trustees Of Dartmouth College | Deimmunized lysostaphin and methods of use |
| US10941182B2 (en) | 2014-06-10 | 2021-03-09 | Amgen Inc. | Apelin polypeptides |
| US11807693B2 (en) | 2014-06-10 | 2023-11-07 | Amgen Inc. | Apelin polypeptides |
| EP4257152A2 (en) | 2014-06-10 | 2023-10-11 | Amgen Inc. | Apelin polypeptides |
| WO2015191781A2 (en) | 2014-06-10 | 2015-12-17 | Amgen Inc. | Apelin polypeptides |
| EP3674314A2 (en) | 2014-06-10 | 2020-07-01 | Amgen, Inc | Apelin polypeptides |
| WO2016033555A1 (en) | 2014-08-28 | 2016-03-03 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| US11414489B2 (en) | 2014-08-28 | 2022-08-16 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| WO2016061286A2 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| US11584923B2 (en) | 2014-10-14 | 2023-02-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| US9969998B2 (en) | 2014-10-14 | 2018-05-15 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
| US12247058B2 (en) | 2014-10-24 | 2025-03-11 | Bristol-Myers Squibb Company | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof |
| US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
| US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
| US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
| US10525170B2 (en)* | 2014-12-09 | 2020-01-07 | Tangible Science, Llc | Medical device coating with a biocompatible layer |
| US11260150B2 (en) | 2014-12-09 | 2022-03-01 | Tangible Science, Inc. | Medical device coating with a biocompatible layer |
| US20170360994A1 (en)* | 2014-12-09 | 2017-12-21 | Tangible Science, Llc | Medical device coating with a biocompatible layer |
| US11142554B2 (en) | 2015-03-18 | 2021-10-12 | Massachusetts Institute Of Technology | Selective Mcl-1 binding peptides |
| US10464975B2 (en) | 2015-07-02 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| US11078246B2 (en) | 2015-08-28 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Peptides binding to Bfl-1 |
| US12102689B2 (en) | 2015-11-09 | 2024-10-01 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| US12391733B2 (en) | 2016-02-29 | 2025-08-19 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| US11945846B2 (en) | 2016-02-29 | 2024-04-02 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
| US12312437B2 (en) | 2016-04-15 | 2025-05-27 | Beckman Coulter, Inc. | Photoactive macromolecules and uses thereof |
| US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
| US11466064B2 (en) | 2016-08-26 | 2022-10-11 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| WO2018039545A2 (en) | 2016-08-26 | 2018-03-01 | Dana-Farber Cancer Institute, Inc. | Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| US12344643B2 (en) | 2016-12-07 | 2025-07-01 | The University Of Chicago | Compositions and methods for inhibition of FOXP3 |
| US12097241B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides |
| US11185570B2 (en) | 2017-02-08 | 2021-11-30 | Bristol-Myers Squibb Company | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides |
| US12097242B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides |
| US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| US11364281B2 (en) | 2017-02-08 | 2022-06-21 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof |
| WO2018170299A1 (en) | 2017-03-15 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of prokaryotic gene transcription and uses thereof |
| WO2018237201A1 (en) | 2017-06-22 | 2018-12-27 | Catalyst Biosciences, Inc. | MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE |
| US12173337B2 (en) | 2017-06-22 | 2024-12-24 | Vertex Pharmaceuticals, Incorporated | Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
| US11401513B2 (en) | 2017-06-22 | 2022-08-02 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
| US11807882B2 (en) | 2017-06-22 | 2023-11-07 | Vertex Pharmaceuticals Incorporated | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
| US10781435B2 (en) | 2017-06-22 | 2020-09-22 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
| US10954501B2 (en) | 2017-06-22 | 2021-03-23 | Catalyst Biosciences, Inc. | Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
| WO2019018499A2 (en) | 2017-07-19 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
| US11325955B2 (en) | 2017-07-19 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
| WO2019118719A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
| WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| US11834520B2 (en) | 2017-12-15 | 2023-12-05 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides |
| WO2019133399A1 (en) | 2017-12-26 | 2019-07-04 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
| US11952432B2 (en) | 2018-02-07 | 2024-04-09 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| WO2019157131A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| WO2019178313A1 (en) | 2018-03-14 | 2019-09-19 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for biomarker detection |
| WO2019191482A1 (en) | 2018-03-30 | 2019-10-03 | Becton, Dickinson And Company | Water-soluble polymeric dyes having pendant chromophores |
| WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| WO2020023300A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Treatment of lymmphatic metastases |
| US12049485B2 (en) | 2018-09-11 | 2024-07-30 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| EP4389145A2 (en) | 2018-09-11 | 2024-06-26 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| WO2020056066A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
| WO2020082057A1 (en) | 2018-10-19 | 2020-04-23 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| WO2020131871A1 (en)* | 2018-12-19 | 2020-06-25 | Tangible Science, Inc. | Systems and methods of treating a hydrogel-coated medical device |
| US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| US12331334B2 (en) | 2018-12-28 | 2025-06-17 | Vertex Pharmaceuticals, Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| WO2020140101A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| WO2020215005A1 (en) | 2019-04-18 | 2020-10-22 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
| US12358960B2 (en) | 2019-04-18 | 2025-07-15 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides |
| WO2021126827A1 (en) | 2019-12-16 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized oncolytic peptides and uses thereof |
| WO2021127493A1 (en) | 2019-12-20 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof |
| WO2021178714A2 (en) | 2020-03-04 | 2021-09-10 | Dana-Farber Cancer Institute, Inc. | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF |
| WO2021183832A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| WO2021216845A1 (en) | 2020-04-22 | 2021-10-28 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
| WO2021222243A2 (en) | 2020-04-27 | 2021-11-04 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized and hdmx-selective p53 peptides and uses thereof |
| WO2021236526A1 (en) | 2020-05-18 | 2021-11-25 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
| WO2021255524A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| WO2022081827A1 (en) | 2020-10-14 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Chimeric conjugates for degradation of viral and host proteins and methods of use |
| WO2022098848A1 (en) | 2020-11-05 | 2022-05-12 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ebolavirus peptides and uses thereof |
| WO2022212899A1 (en) | 2021-04-03 | 2022-10-06 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
| WO2023039474A1 (en) | 2021-09-08 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
| EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
| WO2023215784A1 (en) | 2022-05-04 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof |
| WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
| WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
| US12441775B2 (en) | 2022-08-29 | 2025-10-14 | Dana-Farber Cancer Institute, Inc. | BCL-W polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss |
| WO2024196805A1 (en) | 2023-03-17 | 2024-09-26 | Beckman Coulter, Inc. | Benzothienopyrrole cyanine dyes |
| WO2025064842A1 (en) | 2023-09-21 | 2025-03-27 | Beckman Coulter, Inc. | Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry |
| Publication | Publication Date | Title |
|---|---|---|
| US5446090A (en) | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules | |
| KR100807141B1 (en) | Synthesis of High Molecular Weight Nonpeptidic Polymer Derivatives | |
| US6624246B2 (en) | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) | |
| JP4961025B2 (en) | Non-antigenic branched polymer conjugate | |
| ES2831379T3 (en) | Polymeric derivatives for selective protein modification | |
| KR20020074459A (en) | Sterically hindered derivatives of water soluble polymers | |
| HK1132001A (en) | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) |
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment | Owner name:SHEARWATER POLYMERS, INC., ALABAMA Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARRIS, J. MILTON;REEL/FRAME:006850/0117 Effective date:19940124 | |
| STCF | Information on status: patent grant | Free format text:PATENTED CASE | |
| CC | Certificate of correction | ||
| FPAY | Fee payment | Year of fee payment:4 | |
| AS | Assignment | Owner name:SHEARWATER CORPORATION, ALABAMA Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER POLYMERS, INC.;REEL/FRAME:011295/0671 Effective date:20000927 | |
| FEPP | Fee payment procedure | Free format text:PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY | |
| FPAY | Fee payment | Year of fee payment:8 | |
| AS | Assignment | Owner name:NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:013467/0564 Effective date:20021202 | |
| FPAY | Fee payment | Year of fee payment:12 | |
| AS | Assignment | Owner name:NEKTAR THERAPEUTICS, CALIFORNIA Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394 Effective date:20090731 Owner name:NEKTAR THERAPEUTICS,CALIFORNIA Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394 Effective date:20090731 | |
| AS | Assignment | Owner name:WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATE Free format text:GRANT OF SECURITY INTEREST;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:028571/0141 Effective date:20120711 Owner name:WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, NEW YORK Free format text:GRANT OF SECURITY INTEREST;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:028571/0141 Effective date:20120711 | |
| AS | Assignment | Owner name:NEKTAR THERAPEUTICS, CALIFORNIA Free format text:RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141;ASSIGNOR:WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT;REEL/FRAME:036866/0700 Effective date:20151005 |